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NOTES
1. All the temperatures are expressed in degree centigrade
(0C).
2. Melting Points of all the compounds are uncorrected and
have been recorded by open capillary method.
3. Room temperature, wherever mentioned, normally corresponds
to 280 to 33 0C.
4. Silica gel-G was used for preparing the TLC plates using
different solvent systems.
5. Infra Red spectrum  of all the compounds were scanned on
SHIMADZU-FOURIER TRANSFORM INFRA RED(FTIR) -
8400 SPECTROPHOTOMETER using KBr disc.
6. 1HNMR Spectra were recorded on BRUKER SPECTROPHO
TOMETER (400 MHz) using TMS as a internal standard and
CDCI3 and DMSO-d6 as solvents.
7. MASS spectrum were recorded on SHIMADZU-GCMS-QC-
2010.
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1S y n o p s i s    “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
 A  brief summary of  the work to be incorporated in the thesis entitled
“ STUDIES ON NOVEL SOME BIOACTIVE SYNTHETIC COMPOUNDS ’’ has
been summarized as under.
PART - I STUDIES ON  PYRAZOLO [3,4-d] PYRIMIDINES
PART - II STUDIES ON PYRIMIDINES
PART - III STUDIES ON 4-QUINOLONES
PART - I : STUDIES ON  PYRAZOLO [3,4-d] PYRIMIDINES
Pyrazolo [3,4-d] pyrimidines represents one of the most active classes
of compounds possessing a wide spectrum of biological activities viz.,
anticancer, anti-HIV, antitumor, antiviral, antiparasitic etc., Pyrazolo[3,4-d]-
pyrimidines can be used as a chemotherapeutic agent against neurosfora. It
was thought  worthwhile to synthesize some newer pyrazolo [3,4-d] pyrimidines
which can be summarized as under.
SECTION - I   :Preparation and Biological evaluation of  3-Amino-5-hydro
amino/methyl-4-substituted phenyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-d]
pyrimidin-6-imines/thiones/ones.
N
N
H
X
N
N
H
NH2
R
R1
          (Ia-j)
R = Substituted Phenyl    R1= H,NH2, CH3      X = NH / S / O
3-Amino-5-hydro/amino/methyl-4-substituted phenyl-1,4,5,7-tetrahydro-
6H-pyrazolo[3,4-d]- pyrimidin-6-imino/thiones/ones (Ia-j) have been synthesized
by the condensation of different substituted benzaldehydes, 5-amino-2,4-
dihydro-3H-pyrazol-3-one and guanidine hydrochloride / thiosemicarbazide /
N-methyl urea in the presence of catalytical amount of conc. acid.
2S y n o p s i s    “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
PART - II STUDIES  ON   PYRIMIDINES
Pyrimidines represents one of the most active classes of compounds
possessing a wide spectrum of biological activities viz., significant in vitro
activity against unrelated DNA and RNA viruses including Polio and Herpes
viruses,  diuretics, antitubercular, antihypertensive. Some pyrimidines, which
occurs as natural products like nucleic acids and vitamin-B and can be used
as therapeutic agents for the treatment of AIDS and antitumor.  In view of getting
better theraputic agent of  pyrimidines  it was thought worthwhile to synthesize
some newer pyrimidine derivatives which can be summarized as below.
SECTION-II :Preparation and Biological evaluation of 1-(2-Imino/thio-
nes/ones-6-methyl-4-(4-substituted phenyl)-1,2,3,4-tetrahydropyrimi-
din-5-yl)-ethanones.
N
N
H
X
CH3
O
CH3
R
R1
         (IIa-j)
R = Substituted Phenyl    R1= H,NH2, CH3      X = NH / S / O
1-(2-Imino/thioxo/oxo-6-methyl-4-(4-substituted phenyl)-1,2,3,4-
tetrahydro-pyrimidin-5-l)ethanones (Ia-j) have been synthesized by the
condensation of different substituted benzaldehydes, acetyl acetone and
guanidine hydrochloride/ thiosemicarbazide / N-methyl urea in the presence
of catalytical amount of conc. acid.
3S y n o p s i s    “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
SECTION - III : Preparation and Biological evaluation of 4-Substituted
phenyl - 6 - methyl - 2 -oxo/thioxo/imino-N-(pyridin-2-yl)-
1,2,3,4-tetrahydropyrimidine-5-carboxamides.
R
N
NH NH
N
H
X
O
CH3
(IIa-j)
        R = Substituted Phenyl
4- Substituted phenyl-6-methyl-2-oxo/thioxo/imino-N-(pyridin-2-yl)-
1,2,3,4-tetrahydropyrimidine-5-carboxamides(IIa-j) have been synthesized by
the condensation of different substituted benzaldehydes, 3-oxo-N-(pyridin-2-
yl)-butanamide and urea / thiourea / guanidine hydrochloride in the presence
of catalytical amount of conc. acid.
PART - III : STUDIES ON 4-QUINOLONES
4-Quinolones exhibit a wide spectrum of pharmacological profile such
as antibacterial, antitubercular, antitumar,  non-nucleoside inhibitors of
human cytomegalo virus, new CB-2 cannabinoid receptors agonists,
antimalarials, antifungal, antiinflammatory. Due to the various biological
activities of 4-quinolones in medicinal chemistry, an attempt has been made
to undertake  the synthesis of 4-quinolones as given below.
SECTION - IV :Preparation and Biological evaluation Ethyl-6-chloro/
flouro/methyl/methoxy-7-chloro/methyl -1-N-propyl-1,4-dihydro quinoline-4-
one-3-carboxylates.
(IVa-j)
R = Substituted Phenyl
N
O O
O CH3
CH3
R
4S y n o p s i s    “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
Ethyl-6-chloro/flouro/methyl/methoxy-7-chloro/methyl -1-N-propyl-1,4-dihydro quinoline-
4-one-3-carboxylates (IVa-j) have been prepared by the condensation substituted
4-quinolones with propyl bromide in presence of Dimethyl formamide( DMF)
and Potassium carbonate ( K2CO3 ).
SECTION - V :Prepara t ion  and  Bio log ica l  eva lua t ion  6-Chloro/
flouro/methyl/methoxy/nitro-7-chloro/methyl-1-N-propyl-1,4-dihydro
quinoline-4-one-3-carboxylic acids (Va-j ).
                  (Va-j)
     R = Substituted Phenyl
6-Chloro/flouro/methyl/methoxy/nitro-7-chloro/methyl-1-N-propyl-1,4-dihydro
quinoline-4-one-3-carboxylic acids (Va-j ) have been prepared by hydrolysis of
ethyl-6-chloro/flouro/methyl/methoxy-7-chloro/methyl-1-N-propyl-1,4-dihydro
substituted quinoline-3-carboxylates(IVa-j) in presence of sodium hydroxide (
NaOH).
SECTION -VI :Preparation and Biological evaluation of 6-Flouro-7-N-
ethyl piperazinyl, / N,N-dichloroethyl /  morpholinyl /  N-phenyl piperazinyl /
N-methyl piperazinyl /piperazinyl /  N,N-diethyl amnio  /  2- pyridyl amino  / 2-
amino pyrimidyl-1-N-propyl-1,4-dihydro quinoline-4-one-3-carboxylic
acids(VIa-j ).
     (VIa-j)
R = N-ethyl piperazine,  N,N-dichloroethyl /
     Morpholine /  N-phenyl piperazine / N-methyl
     piperazine /piparazine /  N,N-diethyl amine  /
     2-amino pyridine / 2-amino pyrimidine
N
O O
OH
CH3
R
N
O O
OH
CH3
F
R
5S y n o p s i s    “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
6-Flouro-7-N-ethyl piperazinyl/ N,N-dichloroethyl /  morpholinyl /  N-phenyl
piperazinyl / N-methyl piperazinyl /piperazinyl /  N,N-diethyl  /  2-pyridyl amino
/ 2-pyrimidyl amino -1-N-propyl-1,4-dihydro quinoline-4-one-3-carboxylic
acids(VIa-j ).have been prepared by the condensation of  4 - Oxo-1 - propyl -
1,4-dihydro-quinoline-3-carboxyl ic acid and N-ethyl piperazine/N,N-
dichloroethyl /  morpholine /  N-phenyl piperazine / N-methyl piperazine /
piparazine /  N,N-diethyl amine  /  2-amino pyridine / 2-amino pyrimidine.
PURIFICATION AND STRUCTURAL CHARACTRISATION:
The puri ty of al l  compounds have been tested by thin layer
chromatography using two different solvent systems (Rf1 & Rf2). The
constitution of newly synthesized compounds have been delineated by
elemental analysis, FT-IR, 1H NMR and Mass spectoscopy.
ANTIMICROBIAL ASSAY:
The purified organic compounds have been screened for their in vitro
therapeutic assay like antibacterial activities towards Gram possitive and
Gram negative bacterial strain and antifungal activity towards fungal strain at
different concentrations (Minimum Inhibitory Concentration). The biological
activities of synthesized compounds have been compared with standard drugs
at different concentrations.
S T U D I E S  O N SOME NOVEL BIOACTIVE
SYNTHETIC COMPOUNDS



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STUDIES ON SOME NOVEL BIOACTIVE
SYNTHETIC COMPOUNDS
(A) Drug
The word drug is derived from the French word “drogue” which means
‘a dry herb’. It is the single active chemical entity present in a medicine that
is used for diagnosis, prevention, treatment / cure of a disease. This dis-
ease oriented definition of drug does not include contraceptives or use of
drugs for improvement of health. According to “WHO” a drug may be defined
as “Any  substance or product which is used or intended to be used for modi-
fying or exploring physiological system as pathological status for the benefit
of the recipient”.
(B) Pharmacology
Pharmacology is the science of drugs. In a broad sense, it deals with
interaction of exogenously administered chemical molecules (drugs) with
living system. It encompasses all aspects of knowledge about drugs, but most
importantly those that are relevant to effective and safe use for medicinal
purposes. For thousands of years most drugs were crude natural products of
unknown composition and limited efficiency. Only the over effects of these
substances on the body were rather imprecisely known, but how the same were
produced was entirely unknown. Over the past 100 years or so, drugs have
been purified, chemically characterized and a vast variety of highly potent and
selective new drugs has been developed. The two main divisions of
pharmacology are pharmacodynamics and pharmacokinetics.
(a) Pharmacodynamics : It is derived from the Greek word “dynamic”
means power. What the drugs does to the body? This includes physiologi-
cal and biochemical  ef fects of  drugs and thei r  mechanism of  act ion
at macromolecular / sub cellular organ systems.
7G e n e r a l  I n t r o d u c t i o n    “  S t u d i e s  o n  s o m e  n o v e l  b i o a c t i v e  s y n t h e t i c  c o m p o u n d s . ”
(b) Pharmacokinetics : It is derived from the Greek word ‘Kinesis’
means movement. What the body does to the drug ? This refers to move-
ments of the drug in and alternation of the drug by the body; includes ab-
sorption, d ist r ibut ion,  b inding /  local izat ion /  s torage,  b iotransforma-
t ion and excretion of the drug.
Some other important aspects of pharmacology are given as under :
* Pharmacotherapeut ics  :  I t  i s  t he  app l i ca t i on  o f  pha rmaco-
dynamic information together with knowledge of the disease for its
prevention, mitigation or cure.
* Clinical  Pharmacology :  I t  is  the sc ient i f ic  s tudy of  drug in
man. I t  inc ludes pharmacodynamic and pharmacokinet ic  inves
tigation in healthy volunteers and in patients; evaluation of efficiency
and safety  o f  d rugs  and  compara t i ve  t r i a l s  w i th  o the r fo rms
o f  t rea tmen ts ;  surveillance of patterns of drug uses, adverse
effects, etc.
* Chemotherapy : It is the treatment of systemic infection / malignancy
wi th speci f ic  drugs that  have se lect ive tox ic i ty  for  the in fect
ing organism / malignant cell with less effect on the host cells.
?  Drugs in general, can thus be divided into :
* Pharmacodynamic agents :  These are chemical substances
designed to have pharmacodynamic effect in the recipient.
* Chemotherapeutic agents : These are chemical substances designed
for the treatment of infectious diseases or by the proliferation of malignant cells.
(c) Essential Drug Concept: The ‘WHO’ has defined Essential Drugs
as “those that satisfy the healthcare needs of majority of the population; they
should therefore be available at all times in adequate amounts and in
appropriate dosage form”.
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I t  has been real ized that  only a handful  of  drugs out of  the
multitude available can meet the health needs of majority of the people in any
country, and that may be well tested and cheaper drugs are equally (or more)
efficient and safe as their newer more expensive congeners. For optimum
utilization of resources, governments (specially in developing countries) should
concentrate on these drugs by identifying them as Essential Drugs. The “WHO”
has laid down criteria guide selection of an essential drug :
(I) Adequate data on its efficiency and safety should be available from
          clinical studies.
(II) It should be available in a form in which quality, including bioavailability and
stability on storage can be assured.
(III) Its choice should depend upon pattern of prevalent diseases; avail-
ability  o f  fac i l i t ies  and t ra ined personne l ;  f inanc ia l  resources;
genet ic ,  demographic and environmental factors.
(IV) In case of two or more similar drugs, choice should be made on the
basis of their relative efficiency, safety, quality, price, availabil ity
and cost benefit ratio should be a major consideration.
(V) Choice may also be influenced by comparative pharmacokinetic proper
ties and local facilities for manufacture and storage.
(VI) Most essential drug should be single compound. Fixed ratio combina-
tion products should be included only when dosage of each ingredient
meets the requirements of a defined population group, and when the
combination has a proven advantage.
(VII) Selection of essential drug should be a continuous process which should
take into account the changing priorities for public health action, epide-
miological condition as well as availability of better drugs/ formulations
and progress in pharmacological knowledge.
(C)  Drug Development
Many natural products by trial and error, came into practise for combat-
ing human ailments existent during early human observation. With the advent
of modern scientific approach, various plant medicines came under chemical
scrutiny, ultimately leading to the isolation of active principles since early.
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Such compounds either in extract form or in pure form became a part of
pharmacopoeias. For instance, though the Chinese drug, Mauhang was in use
for over 5000 years for the treatment of various types of fever and respiratory
ailments, its active principle, Ephidrine was isolated in 1887. In 1925 chemi-
cal investigations followed by pharmacological evaluation led this compound
into the modern medicine. Similarly during this period, urea stibamine was
introduced as the first drug in 1920 for the treatment of Kala-azar. In 1930, De
Rauwolfia preparation were first employed for sedative and hypotensive prop-
erties.
A drug is a substance having abnormal effect on certain body functions
eg. Strychnine stimulates the action of heart and aspirin retards its action.
Since both of them effects abnormally, the two substances are known as drugs.
Chemical    sciences contributed extensively new discoveries leading to use-
ful drugs since after 1930. The modern concept of drug discovery started in
1933 by Gerhand Domagk with his finding of “Prontosil Red”, a compound
responsible for the antibacterial activity. The advent of sulphonamides drew
the attention for the different activities of various chemicals for bacterial and
human cells, this important factor prompted Florey and Chain in 1939 to in-
vestigate penicillin which was discovered ten years earlier by Alexander
Fleming. The spectacular chemotherapeutical properties of penicillin and its
dramatic war-time development for the treatment of wounds made penicillin,
a most commonly used inexpensive drug.
           A large number of important drugs have been introduced during the
period of 1940 to 1980. This period is known as “Golden period” of new drug
discovery. Thus starting from 1933 - the first antibacterial drug prontosil lead-
ing to various  sulpha drugs ; 1940 – penicillin ; 1945 – chloroquine – anti-
malarial ; 1950 – Methyldopa – antihypertensive; 1967 – chlorothiazine
-diuretic; 1958 - adrenergic beta blockers coronary vasodilatory; 1960 - semi
synthetic penicillin -antibacterial; 1965 -trimethoprim-antimicrobial;1967-
disodium chromoglycoate - antiallergic; 1972 - cimetidine H2– antagonist;
1975 -verapamil- calciumantagonist and 1981 - captopril - antihypertensive.
There are some specific examples representing new therapeuticagent  eg. Metformine
glipizide-anti diabetic.
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(D) Latest Drug Developments
The current interest in the creation of large, searchable libraries of
organic compounds has captured the imagination of organic chemists and
the drug discovery community. In numerous laboratories the Efforts are focused
on the introduction of chemical diversity, which have been recently reviewed
and pharmacologically interesting compounds have been identified from li-
braries of widely different compositions.
Today, the chief source of agents for the cure, the mitigation or the
prevention of diseases are the organic compounds, natural or synthetic, to-
gether with so-called organometallics. Such agents have their origin in a num-
ber of ways (a) from naturally occurring materials - of both plant and animal
origin, and (b) from the isolation of organic compounds synthesized in labora-
tory whose structures are closely related to those of naturally occurring com-
pounds for eg. atropine, steroids, morphine, cocaine etc. that have been
known to possess useful medicinal properties.
The process of drug design is extensively driven by the instinct  and
experience of pharmaceutical research scientists. It is often instructive to at-
tempt to “capture” these experiences by analyzing the historical record that
are successful drug design projects of the past. From this analysis, the infer-
ences are drawn  which play an important role in shaping our  current and
future projects. Towards this region, we would like to analyse the structures of
a large number of drugs - the ultimate product of a successful drug design
effort. Our goal for this is to  begin to deconvolute this information in order to
apply it to design of new drugs.
Different kinds of drugs are developed for different types of diseases
viz. which can be defined with their names of the modern drugs are as un-
der.
(a) Anticancer drugs
The drugs, which stops the abnormal growth of cell tissues in human
body, are termed as anticancer drug. Vinblastin and Busulphan are the novel
anticancer drugs.
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(b) Hepatoprotective drugs
Drugs, which gives vitality to liver and protects liver by giving immunity
power against antibodies, are termed as Hepatoprotective drug.
(c) Antimalarial drugs
Drugs, which kills the plasmodium causing malaria are called antima-
larial drug. Combination of Sulphamethoxazole with Pyrimethamine is a
novel antimalarial drug.
(d)      Drug for meningitis
Drugs, which cures the inflammation of meningitis, are termed as
meningitis drugs Cifalexin is a novel meningitis drug.
(e)      Drug for typhoid
Drugs, which kills the bacteria of Salmonella typhi causing typhoid are
known as typhoid drugs. A novel drug for typhoid is Ciprofloxacin.
(f)       Antidiabetic drugs
Drugs, which converts the excess glucose of blood into glycogen are
termed as antidiabetic drugs. Novel antidiabetic drugs are Metformin,
Glipizide and Gliclazide.
(g) Antitubercular drugs
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus
cures lesions of pleural cavity. A novel antitubercular drug is Ethambutol.
(h) Antiasthamatic drugs
             Drugs, which prevents the attack of asthama and gives relax respira-
tion are called antiasthamatic drugs. Novel antiasthamatic drugs are
Ethophylline, Theophylline and Asmon.
(i) Antihypertensive drugs
            Drugs, which normalizes the blood pressure by dilating blood vessels
are called antihypertensive drugs. Novel antihypertensive drugs are
Atenolol,  Amlodipine and Nifedipine.
1 2G e n e r a l  I n t r o d u c t i o n    “  S t u d i e s  o n  s o m e  n o v e l  b i o a c t i v e  s y n t h e t i c  c o m p o u n d s . ”
(j)        Anti-AIDS drugs
          Drugs, which kills the viruses of AIDS i.e., HIV-1 and HIV-2 are called
anti-AIDS drugs. Novel drugs are Zidovudine, Acyclovir and Didanosine.
(k) Antacid drugs
           Drugs, which neutralize the acid in stomach and stops excessive
secretion of acid, are called antacid drugs. Novel antacid drugs are
Omeprazole and Lansoprazole.
(l)      Non steroidal antiinflammatory drugs (NSAID)
Drugs, which gives relief from fever, pain and inflammation are called
NSAID. Novel NSAID are Pyroxicam, Meloxicam and Nimesulide.
Different kind of drugs generally used are designed as anaesthetic,
ant i tuberculostat ic,  ant ihypertensive, ant iconvulsant,  anthelmint ic,
antiinflammatory, sedative and hypnotics which prompted us to synthesise
drugs having pyrazolo[3,4-d]pyrimidines, quinazolines and pyrazoles moi-
eties as a better therapeutic activity.
? Aims and objectives of the present investigation are
(a) To generate  severa l  b io log ica l ly  ac t ive  moie t ies  such as
pyrazolo[3,4-d]pyrimidines, quinazolines and pyrazoles.
(b) To characterize these products for their structural assignment using
various spectroscopic techniques like IR, PMR and Mass spectroscopy.
(c) To screen these new derivatives for their antimicrobial activity using
different s t ra ins  o f  bacter ia  and fung i  and to  compare ant imicrob ia l
act iv i ty  with
different known drugs at different concentrations for their MIC values.
In view of these facts, the research work presented in thesis are as
follows.
PA RT- I
STUDIES ON
 PYRAZOLO[3,4-d]PYRIMID INES



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   PART - I
STUDIES ON  PYRAZOLO [3,4-d] PYRIMIDINES
INTRODUCTION
Pyrazolo[3,4-d]pyrimidine [1] is a fused heterocyclic compound in
which pyrimidine with its “d” position is fused at 3 and 4 positions of pyrazole
ring. R. Justoni et.al,1 have synthesized 6-methyl-1,3-diphenyl-1H-pyrazolo-
[3,4-d] pyrimidine-4-(5H)-ones in 1938. Pyrazolo [3,4-d] pyrimidine ring is iso-
meric with the purine [2] and therefore, is of interest as a model for biologi-
cally active compounds. Pyrazolo[3,4-d]pyrimidine is also known as
allopurine.
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[1]     [2]
Pyrazolo[3,4-d]pyrimidine            Purine
There are two other possible isomers of pyrazolo[3,4-d]pyrimidines
[3,4], which are fused at different positions of pyrazole ring and are represented
as under.
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       [3]       [4]
     Pyrazolo[3,2-f]-1,2,4-triazine Pyrazolo[4,3-d]pyrimidine
METHODS FOR SYNTHESIS OF PYRAZOLO[3,4-d]PYRIMIDINES
Extensive studies have been made in the field of synthesis of pyrazolo-
[3,4-d]  pyrimidines. Various methods for the synthesis of pyrazolo[3,4-d] pyri-
midines have been described as under.
(a) By the condensation of 5-Amino-4-cyano-pyrazole with 5-nitro-2-
furonitrile led to formation of 4-amino-6-(5’-nitro-2’-furyl)-1H-pyrazolo [3,4-
d] pyrimidines 2.
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(b) By the cyclocondensation of 4,6-Dichloro-5-formylpyrimidine with
hydrazine hydrate led to formation of 1H-pyrazolo [3,4-d] pyrimidines 3.
(c) By the fusion of 1,3-Dimethyl-6-hydrazino uracil at 150oC with dim-
ethyl formamide dimethylacetal (DMF,DMA) led to formation of 2-alkyl-5,7-
dimethyl pyrazolo [3,4-d] pyrimidine-4,6(5H, 7H)-diones 4.
(d) By the fusion of 5-Arylazo-6-arylidene-hydrazino-1,3-dimethyl
uracils at 200oC led to formation of 2-benzyl-5,7-dimethyl-3-phenylpyrazolo
[3,4-d] pyrimidines-4,6(5H,7H)-diones 5.
(e) By the cyclocondensation of 5-Amino-4-cyano pyrazole with guani-
dine carbonate led to formation of 4,6-diaminopyrazolo [3,4-d] pyrim-
idines6.
(f) By the cyclocondensation of Arylidene derivative of 1,3-diphenyl
uracilwith hydrazine hydrate led to the formation of pyrazolo [3,4-d] pyri-
midines7.
(g) By the cyclocondensation of 4-Carboxamido-5-amino-1,2,3-
trihydropyrazole with formamide led to the formation of pyrazolo[3,4-
d]pyrimidines 8.
(h) By the cyclocondensation of 3,4-Dicyano-5-amino-1-N-substituted
pyrazole  with trichloro acetonitrile led to formation of pyrazolo [3,4-d] pyri-
midines 9.
(i) By the cyclocondensation of 3-Aryl-2-arylamino-5-cyano-6-me-
thyl-sulphonylpyrimidine-4-one with hydrazine hydrate  led to formation
of pyrazolo [3,4-d] pyrimidines 10.
(j) By the cyclization of substituted 5-Amino-1H-pyrazole-4-carbonitrile
with formic  acid or formamide or urea or thiourea or guanidine11.
(k) By the cyclization of substituted Ethyl-(4-cyano-1H-pyrazol-5-yl)
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imidoformate with ammonium hydroxide or hydrazine hydrazide or acid
hydrazide11.
(l) By the cyc l iza t ion o f  2-Chloro-6-methoxy quinol ine-3-
carboxaldehyde and 3-methyl-1-N-phenyl-5-pyrazolone with thiourea led
to formation of pyrazolo [3,4-d] pyrimidines 12.
MECHANISM
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[a]
[b] [c]
[d] [e]
X = NH / S / O.   R= H,NH2,CH3
The present work is explained by considering basic mechanism of
multicomponents biginelli reaction. This includes the condensation of substi-
tuted benzaldehydes [a] with either guanidine or thiosemicarbazide or N-me-
thyl urea  to form hemiaminal [b] with some similarities to the mannich con-
densation. Hemi aminal [b] undergoes dehydration in presence of acid cata-
lyst to produce iminium cation [c] as a intermediate. The enamine (iminium
cation) [c] generated acts as an electrophile for the nucleophilic addition of
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keto enol of pyrazolone with removal of proton to produce [d]. The intermedi-
ate [d] undergoes intramolecular condensation in presence of acid between
oxygen of ketone and amino group of guanidine or thiosemicarbazide or
N-methyl urea to give the cyclised targeted product [e].
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[f][e]
X = O / S / NH.      R= H,CH3,NH2
This mechanism includes the condensation of substituted benzaldehydes
[a] with keto enol of pyrazolone [b] to form intermidiate [c] with some similari-
ties to the aldol condensation. Intermidiate [c] udergoes dehydration in pres-
ence of acid catalyst to produce arylidine [d]. The condensation of arylidene
[d] with either guanidine or thiosemicarbazide or N-methyl urea to form
hemiaminal intermidiate [e]. Hemiaminal intermidiate [e] undergoes intramo-
lecular condensation in presence of acid between oxygen of ketone and amino
group of guanidine or thiosemicarbazide or N-methyl urea to give cyclised
targeted product [f].
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MEDICINAL IMPORTANCE OF PYRAZOLO [3,4-d] PYRIMIDINES
Considerable research has been undertaken to extend the activity and
reduce toxicity of Pyrazolo [3,4-d] pyrimidines. The specific biological activi-
ties of  Pyrazolo [3,4-d] pyrimidines have been represented as under.
(a) Hyperglycemic 13,15 (b) Protozoacidal 16
(c) Hypoglycemic 17 (d) Antimalarial 20
(e) Anticancer 24,25,35,50 (f) Analgesic, antipyretic,
antiinflammatory 26,29,36,46
(g) Antimycotic agent 31 (h) Xanthine oxidase inhibitor 14,34
(i) Antitumor 30,38,47 (j) Anti HIV 40,44
(k) Anxiolytic agent 32 (l) Cardiovascular 23,49,51,53,54
(m) Antileishmanial 39,41,48 (n) Tranquilizer 52
(o) Blood sugar lowering agent 18 (p) Antiparasitic 21
(q) Antianaphylactic agent 22 (r) Coccidiostatic agent 27
(s) Anticonvulsant 42 (t) Antiviral 28,33,37,43,45
(u) Antiallergic 19 (v) Antimicrobial activity56
A.S. Bell et al.,55 have prepared pyrazolo[3,4-d]pyrimidines [05] which
are useful for treatment of memory enhancement, hypertension, congestive heart
failure and female sexual dysfunction.
N
N
N
NH
N
Et
Et
O
CH3
[05]
M. L. Taha et. al,57 have synthesized pyrazolo[3,4-d]pyrimidines [06,07,08]
and were evaluated for their inhibitory effects against the replication of HIV-1,
HIV-2(ROD), various DNA viruses, a variety of tumor-cell lines and tuberculosis.
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R.Riguera et. al,58 have synthesized 1,4 and 6-substituted 1H-pyrazolo
[3,4-d] pyrimidines [09,10,11] and their effect on the release of histamine from
rat peritoneal mast cells measured.
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[09] [10] [11]
M. Friedman et al.,59 have prepared 3-(azo hetero)-aryl-1H-pyrazolo [3,4-
d] pyrimidine-3-amines [12] as protein kinase inhibitors with antiangiogenic
properties.
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J. Markwalder et al.,60 have synthesized 6-substituted pyrazolo [3,4-d]
pyrimidin-4-ones [13] useful as cyclin dependent kinase (cdk) inhibitors for
treating cancer and proliferative diseases. M. M. Ghorab et al.,61 have syn-
thesized novel series of pyrazolo[3,4-d]pyrimidine [14] and evaluated for anti-
microbial activity comparable to antibiotic Chloramphenicol as standard anti-
bacterial agent and Terbinafin as a standard antifungal agent.
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K.H.Yoo et. al, 62 have prepared 1,4,6-trisubstituted pyrazolo [3,4-d]
pyrimidines [15,16] which are useful for better CDK2 inhibitory activity and
antitumour  activity.
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S.R.Shin et. al,63 have synthesized a series of pyrazolo [3,4-d]
pyrimidines [17] which are evaluated in a plaque reduction assay. This class
of compounds provide remarkable evidence that they are very specific for hu-
man enteroviruses, in particular, coxsackieviruses.
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[17]
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B.S.Holla et. al,64 have synthesized pyarazolo[3,4-d]pyrimidine [18] as anti-
bacterial and antifungal properties. R. D. Hubbard et al.,65 have prepared
pyrazolo[3,4-d]pyrimidine [19] which are useful for kinase inhibitors possessed
moderate potency for insulin-like growth factor receptor (IGR-IR), a promis-
ing target for cancer chemotherapy.
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[18] [19]
Recently, R.Ducray et.al,66 have synthesized novel 4-anilino-1H-
pyrazolo[3,4-d]pyrimidines [20] and evaluated in vitro for erbB2 and epider-
mal growth factor receptor (EGFR) kinase inhibition. Overexpression of EGFR
and erbB2 has been implicated in the development of various types of cancer.
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PHARMACOLOGY OF RECENT DRUGS:
The most successful and well understood pyrazolo[3,4-d]pyrimidine com-
pound is acyclovir [21], which is highly active against herpes simplex virus
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(HSV), varicella zoster virus infections and is used clinically.67,68 Acyclovir
is a 2’-deoxyguanosine analoge that contains an acyclic side chain in place of
the deoxyribose ring. It contains all of the atoms of 2’-deoxyguanosine, with
the exception of the 2’- and 3’-carbons and 3’-hydroxy group of the deoxyribose
ring.
N
NH
N
N
O
NH2
OOH
[21]
Like most nucleoside analogous, acyclovir is a prodrug. Unlike other
necleoside analogous such as 3-Azido-3’deoxythymidine(AZT), however,
prodrug activation is one of the mechanisms by which acyclovir obtains selec-
tivity. The compound has a selectivity index of approximately 3000; the IC50
is 300mM for inhibition of HSV-1, while the IC50 is 300mM for cytotoxicity to
host Vero cells in vitro.67 This selectivity is derived from two different mecha-
nisms: Differential activation of acyclovir in infected cells and increased po-
tency against HSV DNA polymerase. Acyclovir is phosphorylated 30 to 120
times faster with extracts from HSV-1-infected cells compared to uninfected
cell extracts.68 Moreover, the ki values for HSV-encoded DNA polymerases
are 10 to 40 times lower than for cellular DNA polymerases.67 Thus the active
form of acyclovir is present in greter quntities within virally infected cells and
is also more potent against viral DNA polymerase.
Activation of acyclovir to its triphosphate form is mediated by both viral
and cellular enzymes. Virally encoded thymidine kinase produces acyclovir
monophosphate, which is further phosphoryalated by cellular GMP kinase to
the diphosphate derivative. The diphosphate is converted to acyclovir triph-
osphate derivative by cellular kinases such as phosphoglycerate kinase. There
are several lines of evidence that supports HSV thymidine kinase as a key
enzyme for the antiviral effect of acyclovir.67 Perhaps the most convincing
evidence is derived from studies with thymidine kinase-deficient mutants of
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HSV, which are resistant to acyclovir because no phosphorylation occurs within
infected cells.
The triphosphate form of acyclovir inhibits DNA polymerase. The mecha-
nism of inhibition is complex and may involve enzyme inactivation.69 Initially,
the compound competes with dGTP for binding to the polymerase-template
complex. Following binding, it has been suggested that enzyme inactivation
occurs by the formation of a tight,irreversible enzyme-DNA-acyclovir triphos-
phate ternary complex. Addition of dGTP to this complex does not release
active viral DNA polymerase. Interestingly, DNA polymerase from the host cell is
not inactivated in this manner. In addition to dGTP complition and enzyme
inactivation,acyclovir triphosphate inactivates the viral DNA template by chain
termination, since it does not contain  3’-OH group necessary for the addition
of subsequent dNTPs.70 In virally infected cells, incomplete DNA replication
occurs upon treatment with acyclovir.71
Several analoges of acyclovir have been investigated, both at the
level of the target enzymes and for antiviral effect. Various alterations to
the aliphatic side chain of acyclovir are tolerated by the HSV thymidine ki-
nase, as long as the terminal hydroxy group is retained for phosphorylation72.
However, the enzyme is far less tolerant of modification to the heterocyclic
base moiety. Since the pyrimidines are the natural substrates for the viral thy-
midine kinase, it seems logical to predict that pyrimidine analogs of acyclovir
might be good kinase substrates and antiviral agents. However, this is not the
case. Similarly, among purine analogs, only those containing guanine are good
substrates for the viral  enzyme72.
Gaciclovir [22] is an acyclovir analogs that contains an additional
hydroxymethyl group in the side chain73. Because this compound contains
groups that mimic both, the 5’-OH and 3’-OH groups of deoxyguanosine, it
does not act as a chain terminator for DNA synthesis. Nevertheless, compound
[23] is selectively phosphorylated by the viral thymidine kinase and, as the
triphosphate form, inhibits Herpes Simplex virus-1(HSV-1, HSV-2) poly-
merase76. Gaciclovir has been reported to be superior to acyclovir against
human cytomegalovirus (HCMV). Although the compound is converted to the
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triphosphate form in HCMV-infected cells, the enzymes responsible for this
transformation are not yet known. There is no evidence that HCMV encodes a
thymidine kinase.
Among acyclovir analogs, the cyclic monophosphate derivative has been
reported to have the broadest spectrum of activity against DNA viruses.68,75
Within cells, compound [23] is converted to the (S) enantiomer of ganciclovir
monophosphate [24], the same compound that is obtained from phosphoryla-
tion of [22] by HSV-1 thymidine kinase. Other analogs that have been pre-
pared includes compound [25] and a series of related derivatives68,76. These
compounds have a similar mechanism as acyclovir, and several compounds
have comparable antiviral activity.
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[22]           [23]                [24]     [25]
In view of procuring highly potent biodynamic agents and after reviewing
literature survey on pyrazolo[3,4-d]pyrimidines for their various  pharmaco-
logical activities, synthesis of pyrazolo[3,4-d]pyrimidines have been under-
taken which can be summarized in the following section as under.
SECTION - I   : Preparation and biological evaluation of 3-Amino-5-
hydro/amino/methyl-4-substituted phenyl-1,4,5,7-tetrahydro-6H-
pyrazolo[3,4-d] pyrimidin-6-imines / thiones / ones.
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SECTION - I
SECTION - I   : PREPARATION AND BIOLOGICAL EVALUATION OF 3-
AMINO-5-HYDRO/AMINO/METHYL-4-SUBSTITUTED PHENYL-1,4,5,7-
TETRAHYDRO-6H-PYRAZOLO[3,4-D]PYRIMIDIN-6-IMINIES/ONES/
THIONES (Ia-d’).
Keeping in view of wide spectrum biodynamic activit ies13-56 o f
pyrazolo[3,4-d]pyrimidines and with a view to have potent therapeutic
agents, the synthesis of 3-Amino-5-hydro/amino/methyl-4-substituted phe-
nyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-d]pyrimidin-6-imines/ones/
thiones (Ia-j) have been synthesized by the condensation of different substi-
tuted benzaldehydes, 5-amino-2,4-dihydro-3H-pyrazol-3-one and guani-
dine hydrochloride / thiosemicarbazide / N-methyl urea in the presence
of acid.
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H
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(Ia-d’)
R = Substituted Phenyl
R1 = H / NH2 /CH3
X = NH / S / O
The constitution of the products (Ia-d’) have been delineated by
elemental analyses, IR, PMR and Mass spectral data.
The products (Ia-d’) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 (Gram positive), S.
aureus MTCC-96 (Gram positive) and P.Aeruginosa MTCC 424 (Gram nega-
tive) and E. coli MTCC-443 (Gram negative) bacterial strain and antifungal
activity towards Aspergillus niger  MTCC-282 and A.Clavatus MTCC 1323
at different concentrations  : i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for
their MIC (Minimum Inhibitory  Concentration) values. The biological ac-
tivities of the synthesized compounds (Ia-d’) were compared with standard
drugs viz. Amplicilline, Chloramphenical, Ciprofloxacin, Norfloxacin,
Griseofulvin and Nystatin.
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REACTION SCHEME
    (Ia-d’)
R = Substituted Phenyl
R’ = H / NH2/ CH3
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-AMINO-5-HYDRO/
AMINO/METHYL-4-SUBSTITUTED PHENYL-1,4,5,7-TETRAHYDRO-6H-
PYRAZOLO[3,4-D]PYRIMIDIN-6-IMINIES/ONES/THIONES (Ia-d’).
(A) Preparation of 5-Amino-2,4-dihydro-3H-pyrazol-3-one.
For preparation refer refernce no. 80
(B) Preparation of 3-Amino-5-hydro/amino/methyl-4-substituted phe-
nyl-1,4,5,7-tetrahydro-6H-pyrazolo[3,4-d]pyrimidin-6-imines(Ib)
A mixture of 5-Amino-2,4-dihydro-3H-pyrazol-3-one (0.99gm, 0.01M),
p-methoxy benzaldehyde (1.36 ml, 0.01 M), guanidine hydrochloride (1.43
gm, 0.015 M) and catalytical amount of acid in ethanol (30 ml)  was heated
under reflux condition for 8 to 10 hrs. The reaction mixture was kept at room
temperature for two hrs. The yellow crystalline product obtained was isolated
and recrystallized from ethanol. C12H14N6O Yield : 82%, M.P. : 180°C, (Re-
quired : C, 55.78%; H, 5.46%; N, 32.54, O, 6.19% for C12H14N6O Found :
C, 55.67%; H, 5.59%; N, 32.49% O, 6.21%).
TLC  solvent system  Rf1  :  Ethyl acetate : Hexane (3.5 : 6.5)         = 0.48.
TLC  solvent system  Rf2  :  Methanol         : Chloroform (1.0 : 9.0) = 0.70.
Similarly, other compounds (Ia-d’) were synthesized. The physical data
are recorded in Table No. 1a,1b,1c.
(C) 3-Amino-5-hydro/amino/methyl-4-substituted phenyl-1,4,5,7-
tetrahydro-6H-pyrazolo[3,4-d]pyrimidin-6-imines/ones/thiones(Ia-d’).
Antimicrobial activity testing was carried out by using cup-plate
method77, which has been described as under. And results is given in table
No. 1A,1B,1C,1D,1E,1F,1G,1H,1I as given under.
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 Evaluation Techniques :-
# The following conditions must be met for the screening of antimicrobial
activity:
- There should be intimate contcact between the test organisms
and substance to be evaluated.
- Required conditions should be provided for the growth microor
ganisms.
- Conditions should be same through the study.
- Aseptic/sterile environment should be maintained.
Various methods have been used from time to time by several
workers to evaluate the antimicrobial activity. The evalutaion can be done by
the following methods :
- Turbidometric method.
- Agar streak dilution method.
- Serial dilution method.
- Agar diffusion method.
# Following Techniques are used as agar diffusion method:
- Agar cup method.
- Agar ditch method.
- Paper disc method.
We have used the Agar cup mehtod to evaluate the antibacterial activ-
ity.
It is one of the non automated in vitro bacterial susceptibility tests.
This classic method yields a zone of inhibition in mm results for the
amount of antimicrobial agents that is needed to inhibit growth of specific
microoganisms. It is carried out in petriplates.
DETERMINATION OF MINIMAL BACTERICIDAL CONCENTRATIONS BY
AGAR CUP METHOD
MATERIALS AND METHOD:-
1. All the Synthesized Drugs were used for antibacterial test proce
dures.
2. All necessary controls like :
- Drug Control
- Vehicle control
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- Agar control
- Organism control
- Known antibacterial drugs control
- All MTCC cultures were tested againts above mentioned known and
unknown drugs.
- Mueller hinton broth was used as nutrient medium to grow and dilute the
drug suspension for the test.
- Inoculum size for the test strain was adjust to 108 Cfu [colony forming
unit] per milliliter by comparing the turbidity.
- Following common standard strains were used for the screening of an
tibacterial and antifungal activities:
The strains were procured from Institute of microbial technology,
chandigarh.
- Escherichia coli [Gram negative] MTCC-442
- Pseudomonas aeruginosa [Gram negative] MTCC-441
- Staphylococcus aureus [Gram Positive] MTCC-96
- Streptococcus pyogenes [Gram Positive] MTCC-443
- Aspergillus niger [Fungus] MTCC-282
- Aspergillus clavatus [Fungus] MTCC-1323
(DMSO) was used as diluents/vehicle to get desired concentration of drugs to
test upon standard bacterial strains.
ANTIBIOTIC ASSAY AS PER BRITISH PHARMOCOPEIAS (BP)
[Eur. method 2.7.] The potency of an antibiotic is estimated by comparing the inhibi-
tion of growth of sensitive micro-organisms produced by known concentrations of the
antibiotic being examined and a reference substance.
The reference substances used in the assays are substances whose activity has been
precisely determined with reference to the corresponding international standard or
international reference preparation.
The assay must be desingned in a way that will permit examination of the validity of the
mathematical model on which the potency equation is based. If a parallel-line model is
chosen, the two log dose-response (or transformed response) lines of the preparation
being examined and the reference preparation must be parallel; they must be linear
over the range of doses used in the calculation. These conditions must be verified by
validity tests for a given probability, usually P = 0.05. Other mathematical models, such
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as the slope ratio model, may be used provided that proof of validity is demonstrated.
Unless otherwise stated in the monograph, the fiducial limit of error (P=0.95) of the
assay for potency are not less than 95 % and not more than 105 % of the estimated
potency.
Carry out the assay by method A or method B unless otherwise speicified in the mono-
graph.
A. DIFFUSION METHOD
1) Liquefy a medium suitable for the conditions of the assay and
2) Inoculate it at a suitable temperature, for example 48oC to 50oC for vegetative
forms, with a known quantity of a suspension of micro-organisms sensitive to the anti-
biotic being examined such that clearly defined zones of inhibition of suitable diam-
eter are provided with the concentrations of the antibiotic used for the assay.
3) Immediately pour into petri dishes or large rectangular dishes a quantity of the
inoculated medium to form a uniform layer 2 mmm to 5 m thick. Alternatively, the me-
dium may consist of two layers, only the upper layer being inoculated.
4) Store the dishes so that no appreciable growth or death of the micro-organ-
isms occurs before the dishes are used and so that the surface of the medium is dry at
the time of use.
5) Using the solvent and the buffer solution indicated in Table A-1, prepare solu-
tions of the reference substance and of the antibiotic being examined having known
concentrations and presumed to be of equal activity.
6) Apply the solutions to the surface of the medium, for example, in cavities pre-
pared in the agar. The same volume of solution must be added to each cylinder or
cavity.
OR
7) Alternatively, use sterile absorbent paper of suitable quality; impregnate the
discs with the solutions of the reference substance or the soulutions of the antibiotic
being examined and place on the surface of the agar.
8) In order to assess the validity of the assay, use not fever than doses of the
reference substance and three doses of the antibiotic being examined having the same
presumed activity as the doses of the reference substance.
9) It is preferable to use a series of doses in geometric progression. In routine
assays when the linearity of the some system has been demonstrated over an adquate
number of experiments using a three-point assay, a two-point assay may be sufficient,
subject to agreement by the component authority. However, in all cases of dispute, a
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three point assay as decribed above must be applied.
10) Arrange the solutions on each petri dish on each rectangular dish according to
a statistically suitable design, except for small petri dishes that cannot accommodate
more than six solutions, arrange the solutions of the antibiotic being examined and the
solutions of the reference substance in an alternate manner to avoid interaction of the
more concentrated solutions.
11) Incubate at a suitable temperature for about 18 hours. A period of diffusion
prior to incubation, usually 1 to 4 hours, at room temperature or at about 4oC, as ap-
propriate, may be used to mininize the effects of the variation in time between the
application of the solutions and to improve the regression slope.
12) Measure the diameters with a precision of at least 0.1 mm or the areas of the
circular inhibition zones with a corresponding precision and calcuate the potency us-
ing appropriate statistical methods.
13) Use in each assay the number of replications per doses sufficient to ensure the
required precision.
14) The assay may be repeated and the results combined statistically to obtain the
required precision and to ascertain whether the potency of the antibiotic being exam-
ined is not less than the minimum required.
# BUFFER SOLUTION
Weight / 1000 ml.
Adjust the pH by using 8 M phosphoric acid or 10 M potassium hydroxide.
Buffer No.
B1
B2
B3
B4
B5
B6
K2HPO4
02.00
16.73
-
20.00
35.00
13.60
KH2PO4
08.000
00.523
13.610
80.000
-
04.000
pH
6.0
8.0
4.5
6.0
10.5
7.0
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-NH2
Aromatic and
ring skeletal
vibration
Pyrazolo
Pyrimidine
Moiety
Subtitution
Para(-4-)
substituted
Frequency in cm-1
Observed Reported
Reference
3300-3700
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   780
1360 - 1310
1690 - 1650
1220 - 1020
3300-3700
1650 - 1550
1050 - 1010
800 - 850
Type  Vibration  mode
N-H (str., v)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C=N  (str., v)
N-N  (def., v)
N-H (str., m)
N-H (def., s,m)
C-O (str., s)
C-H (def., v,s)
3621.47
3021.44
1462.09
1069.56
826.17
1332.86
1668.48
1211.20
3481.63
1565.29
1025.20
826.17
309
309
310
310
311
311
311
312
312
310
311
312
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
N H
N
H
N
N
H
NH 2
N H
O
C H 3
IR SPECTRAL STUDY OF 3-AMINO-4-METHOXY-PHENYL-1,4,5,7-
TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-IMINE(Ib).
(Ib)
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-NH2
Aromatic and
ring skeletal
vibration
Pyrazolo
Pyrimidine
Moiety
Subtitution
Para(-4-)
substituted
Frequency in cm-1
Observed Reported
Reference
3300-3700
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   780
1690 - 1650
1220 - 1020
3300-3700
1650 - 1550
1050 - 1010
800 - 850
Type  Vibration  mode
N-H (str., v)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C=N  (str., v)
N-N  (def., v)
N-H (str., m)
N-H (def., s,m)
C-O (str., s)
C-H (def., v,s)
3647.51
3016.52
1449.91
1066.52
822.17
1650.16
1242.20
3586.75
1553.46
1025.52
815.92
310
310
312
309
311
312
311
311
312
311
311
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
N
N
H
N
N
H
NH 2
S
O
C H3
N H2
IR SPECTRAL STUDY OF 3,5-DIAMINO-4-METHOXY-PHENYL-1,4,-5,7-
TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-THIONE(Ii).
(Ii)
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-NH2
Aromatic and
ring skeletal
vibration
Pyrazolo
Pyrimidine
Moiety
Subtitution
Para(-4-)
substituted
Frequency in cm-1
Observed Reported
Reference
3300-3700
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   780
1690 - 1650
1220 - 1020
3300-3700
1650 - 1550
1050 - 1010
800 - 850
Type  Vibration  mode
N-H (str., v)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C=N  (str., v)
N-N  (def., v)
N-H (str., m)
N-H (def., s,m)
C-O (str., s)
C-H (def., v,s)
3688.02
3058.06
1449.91
1082.40
782.01
1672.34
1220.07
3450.77
1572.04
1022.40
830.38
312
311
311
309
311
311
311
309
311
312
309
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
N
N
H
N
N
H
NH2
O
O
CH3
CH3
IR SPECTRAL STUDY OF  3-AMINO-4-METHOXY-PHENYL-5-METHYL-
1,4,5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-ONE(Iv).
(Iv)
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Serial
No.
Signal Position
(δ ppm)
Relative No.
of Protons
Multiplicity Inference
1
2
3
4
5
singlet
singlet
singlet
doublet
doublet
- NH2,NH(a)
- NH(b)
- CH(c)
- Ar-H(d,d’)
- Ar-H(e,e’)
4.0902
11.5615
5.4270
7.7683-7.7862
6.9668-6.9788
3H
1H
1H
2H
2H
(Ib)
N
H
N
NH2
N
H
NH
NH
NO 2
a
a
b
c
d'd
e e'
PMR SPECTRAL STUDY OF 3-AMINO-4-NITRO-PHENYL-1,4,5,7-
TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-IMINE(Ib).
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Serial
No.
Signal Position
(δ ppm)
Relative No.
of Protons
Multiplicity Inference
1
2
3
4
5
6
7
singlet
singlet
singlet
doublet
doublet
singlet
singlet
- NH(a’),NH2(a)
- NH(b)
- CH(c)
- Ar-H(d,d’)
- Ar-H(e,e’)
- OCH3(f)
- NH2(g)
4.0812
11.1909
5.7540
7.6024-7.6242
6.8879.-6.9097
3.8312
2.1656
3H
1H
1H
1H
3H
1H
1H
(Ii)
N
N
H
N
N
H
NH2
S
O
CH3
NH2
a
b
a'
c
d d'
e e'
f
g
PMR SPECTRAL STUDY OF 3,5-DIAMINO-4-METHOXY-PHENYL-1,4,-
5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-THIONE(Ii).
3 9P a r t  -  I “  S tud i e s  on  some  nove l  b ioac t ive  synthet i c  compounds . ”
Serial
No.
Signal Position
(δ ppm)
Relative No.
of Protons
Multiplicity Inference
1
2
3
4
5
6
7
8
singlet
singlet
singlet
doublet
doublet
singlet
singlet
singlet
- NH2(a)
- NH(b)
- CH(c)
- Ar-H(d,d’)
- Ar-H(e,e’)
- OCH3(f)
- CH3(g)
-NH(a’)
3.9611
11.6148
5.8603
7.5803-7.5929
6.9258-6.9326
3.8381
2.8603
5.9603
2H
1H
1H
2H
2H
3H
3H
1H
PMR SPECTRAL STUDY OF  3-AMINO-4-METHOXY-PHENYL-5-METHYL-
1,4,5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-ONE(Iv).
N
N
H
N
N
H
NH2
O
O
CH3
CH3
a
b
a'
c
d d'
e e'
f
g
(Iv)
4 0P a r t  -  I “  S tud i e s  on  some  nove l  b ioac t ive  synthet i c  compounds . ”
M
A
S
S
  S
PE
C
TR
A
L 
 S
TU
D
Y 
 O
F 
  3
-A
M
IN
O
4-
(p
-M
E
TH
O
X
Y
P
H
E
N
Y
L)
-1
,4
,5
,7
-T
ET
R
A
H
YD
R
O
-6
H
-P
YR
A
ZO
LO
 [3
,4
-d
]-
PY
R
IM
ID
IN
-6
-IM
IN
E  
(I b
).
(I b
)
N H
N
N
H
2
N H
N
H
N
H
O
C
H
3
4 1P a r t  -  I “  S tud i e s  on  some  nove l  b ioac t ive  synthet i c  compounds . ”
NH
N
N
N
H
OH
NH
N
H
N
N
H
NH
O
CH3
NH
N
H
N
N
H
O
CH3
NH
N
H
N
N
H
NH
N
H
N
N
H
NH2
NH
O
CH3
m/z = 244 (B.P.)
m/z = 258
m/z = 229
m/z = 213
m/z = 200
N
N
H
O
CH3
m/z = 186
NH
N
H
NH
N
H
NH2
NH
m/z = 157
N
N
OH
m/z = 171
NH
N
H
NH
N
H
NH2
m/z = 145
NH
N
H
NH
N
H
m/z = 128
(Ib)
4 2P a r t  -  I “  S tud i e s  on  some  nove l  b ioac t ive  synthet i c  compounds . ”
M
A
S
S
  S
PE
C
TR
A
L 
 S
TU
D
Y 
 O
F 
  3
,5
-D
IA
M
IN
O
-4
-M
E
TH
O
X
Y-
P
H
E
N
Y
L-
1,
4,
-5
,7
-T
E
TR
A
H
Y
D
R
O
-6
H
-P
Y
R
A
ZO
LO
 [3
,4
-d
]
P
Y
R
IM
ID
IN
-6
-T
H
IO
N
E
(I i
).
N H
NN
H
2
N H
N
SN
H
2
O
C
H
3
(I l
)
4 3P a r t  -  I “  S tud i e s  on  some  nove l  b ioac t ive  synthet i c  compounds . ”
N
N
H
N
N
H
NH2
S
NH2
O
CH3
N
N
H
NH2
O
CH3
O
m/z = 217
N+
NH2 S
NH2
O
CH3
m/z = 209
N
N
H
NH
N
H
NH2
SH
NH2
m/z = 192
N
N
H
NH
N
H
S
NH2
m/z = 173
N
N
N
N S
m/z = 149
NH
NH
N
H
SH
m/z = 133
N
N
H
N
N
m/z = 119
O
CH3
m/z = 108
m/z = 290
(Ii)
4 4P a r t  -  I “  S tud i e s  on  some  nove l  b ioac t ive  synthet i c  compounds . ”
M
A
S
S
  S
PE
C
TR
A
L 
 S
TU
D
Y 
 O
F 
  3
-A
M
IN
O
-4
-M
E
TH
O
X
Y-
P
H
E
N
Y
L-
5-
M
E
TH
Y
L-
1,
4,
5,
7-
TE
TR
A
H
Y
D
R
O
-6
H
-P
Y
R
A
ZO
LO
[3
,4
-d
] P
Y
R
IM
ID
IN
-6
-O
N
E
(I v
).
N H
N
N
H
2
N H
N
OC
H
3
O
C
H
3
(I v
)
4 5P a r t  -  I “  S tud i e s  on  some  nove l  b ioac t ive  synthet i c  compounds . ”
N
N
N
N
O
CH3
CH3
NH
N
H
N
N
H
O
N
N
N
N
NH
O
O
CH3
CH3
N
N
H
N
N
H
NH2
O
O
CH3
CH3NH
N
H
NH2
m/z = 268
m/z = 241
m/z = 217
m/z = 177
N+
NH2 O
CH3
m/z = 161
N
N
H
N
N O
CH3
m/z = 149
N
N
N
N
CH3
m/z = 133
N
N
N
N
m/z = 118
m/z = 273
(Iv)
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           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ia-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 1A : COMPARATIVE ANTIMICROBIAL ACTIVITY OF  3-AMINO-4-SUBSTITUTED PHENYL-1,4,5,7-
TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-IMINES(Ia-j). (Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 12 14 16 18
- 13 15 17 18
- 11 14 17 19
- 11 14 15 18
- 12 14 18 21
- 11 14 16 19
- 12 14 16 21
- 12 14 15 18
- 13 14 15 18
11 14 16 17 19
 Compd
 No.
Ia
Ib
Ic
Id
Ie
If
Ig
Ih
Ii
Ij
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 12 15 18 19
- 11 14 16 18
- 12 14 15 17
- 12 16 17 19
- 10 13 15 17
- 11 13 15 16
- 11 15 16 18
- 12 14 14 16
- 10 12 15 16
- 12 14 15 16
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
Ij Ib Ij Ie Ic
Ii Ie
Ij Ig
Ij
Ia Ih Ia Ia
Ib Ij Ib Ib
Ic Ig Id Id
Id Ig Ig
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ia-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 1B : COMPARATIVE ANTIMICROBIAL ACTIVITY OF  3-AMINO-4-SUBSTITUTED PHENYL-1,4,5,7-
TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-IMINES (Ia-j). (Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 17 18 18 21
10 15 17 19 24
08 12 14 16 18
09 14 16 18 19
- 15 17 19 24
- 13 14 15 16
- 15 15 18 19
- 14 16 17 18
09 15 18 20 24
- 12 12 14 15
 Compd
 No.
Ia
Ib
Ic
Id
Ie
If
Ig
Ih
Ii
Ij
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
10 13 15 18 20
- 14 15 18 21
10 10 12 14 17
- 13 15 17 21
10 12 15 18 22
- 11 12 14 17
- 13 14 15 17
- 10 12 14 16
12 15 16 19 23
- 10 11 14 16
                          E. Coli MTCC-443                                                        P. Aeruginosa MTCC-1688
 Amoxiciline
 Chloramphenicol
 Sparfloxacin
 Levofloxacin
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
Ii Ia Ia Ia
Ib Ib Ib
Id Ie Id
Ie Ii Ie
Ii Ii
Ia Ia Ih Ib Ia
Ib Ib Ii Ie Ib
Ie Id Ii Ie
Ig Ie Ii
Ii
48
P
a
r
t
 
-
 
I
P
a
r
t
 
-
 
I
P
a
r
t
 
-
 
I
P
a
r
t
 
-
 
I
P
a
r
t
 
-
 
I
 
“
 
S
t
u
d
i
e
s
 
o
n
 
s
o
m
e
 
n
o
v
e
l
 
b
i
o
a
c
t
i
v
e
 
s
y
n
t
h
e
t
i
c
 
c
o
m
p
o
u
n
d
s
.
”
 
“
 
S
t
u
d
i
e
s
 
o
n
 
s
o
m
e
 
n
o
v
e
l
 
b
i
o
a
c
t
i
v
e
 
s
y
n
t
h
e
t
i
c
 
c
o
m
p
o
u
n
d
s
.
”
 
“
 
S
t
u
d
i
e
s
 
o
n
 
s
o
m
e
 
n
o
v
e
l
 
b
i
o
a
c
t
i
v
e
 
s
y
n
t
h
e
t
i
c
 
c
o
m
p
o
u
n
d
s
.
”
 
“
 
S
t
u
d
i
e
s
 
o
n
 
s
o
m
e
 
n
o
v
e
l
 
b
i
o
a
c
t
i
v
e
 
s
y
n
t
h
e
t
i
c
 
c
o
m
p
o
u
n
d
s
.
”
 
“
 
S
t
u
d
i
e
s
 
o
n
 
s
o
m
e
 
n
o
v
e
l
 
b
i
o
a
c
t
i
v
e
 
s
y
n
t
h
e
t
i
c
 
c
o
m
p
o
u
n
d
s
.
”
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ia-j) with known choosen standard drugs
TABLE NO. 1C : COMPARATIVE ANTIMICROBIAL ACTIVITY OF  3-AMINO-4-SUBSTITUTED PHENYL-1,4,5,7-
TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-IMINES (Ia-j). (Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 17 21 22 23
- 17 19 22 25
- 19 21 23 23
- 20 22 25 27
- 22 25 25 25
- 18 20 22 23
- 18 19 22 25
- 21 22 23 25
- 19 22 25 25
- 18 18 21 22
 Compd
 No.
Ia
Ib
Ic
Id
Ie
If
IIg
Ih
Ii
Ij
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 18 18 21 22
- 22 22 24 24
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
- 18 20 22 22
- 21 22 23 25
- 19 21 22 25
- 21 23 25 27
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
                  A. niger MTCC-282                                               A. clavatus MTCC-1323
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
Griseofulvin
Nystatin
Ic Ie Id
Id Ie
Ie Ii
Ih
Ii
Ib Ib Ib Ib
Id Ih Id Id
Ih Ij Ig Ih
Ij Ih Ii
Ii Ij
Ij
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”
           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ik-t) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 1D : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 3,5-DIAMINO-4-SUBSTITUTED PHENYL-1,4,5,7-
TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-THIONES.(Ik-t).(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 12 13 15 18
- 12 14 18 20
- 11 15 17 20
- 12 13 14 17
- 12 14 15 21
- 12 15 17 18
- 12 13 14 17
- 11 13 14 17
- 12 13 15 20
- 11 12 15 18
 Compd
 No.
Ik
Il
Im
In
Io
Ip
Iq
Ir
Is
It
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 10 11 12 12
- 11 12 15 17
10 14 15 16 18
- 11 14 15 16
- 13 15 16 17
- 10 12 15 17
- 12 14 17 18
- 12 14 15 15
12 15 16 17 18
10 14 14 15 17
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
Im
Io
Is
It
Im
In
Io
Iq
Ir
Is
It
Im
Is
It
Im
Io
Iq
Is
Im
Iq
Is
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
Il Il
Im
Io
Is
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ik-t) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 1E : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 3,5-DIAMINO-4-SUBSTITUTED PHENYL-1,4,5,7-
TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-THIONES.(Ik-t).(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
10 12 13 15 18
- 17 18 18 19
- 12 13 17 20
- 11 11 14 15
08 15 15 18 26
- 11 13 17 17
- 13 13 15 15
- 13 15 16 17
- 15 16 15 17
12 15 17 20 25
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 11 13 15 17
10 12 13 15 17
- 11 11 13 14
- 14 17 18 20
09 12 15 20 23
- 10 12 12 14
- 10 11 12 14
- 11 14 17 19
- 10 14 15 18
10 15 18 20 21
                          E. Coli MTCC-443                                                        P. Aeruginosa MTCC-1688
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
 Compd
 No.
Ik
Il
Im
In
Io
Ip
Iq
Ir
Is
It
Il Il It Im
Is Io
It It
It In In In
Io Io Io
It It It
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIa-j) with known choosen standard drugs
TABLE NO. 1F : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 3,5-DIAMINO-4-SUBSTITUTED PHENYL-1,4,5,7-
TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-THIONES.(Ik-t).(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 22 22 24 24
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
- 18 20 22 22
- 21 22 23 25
- 19 21 22 25
- 21 23 25 27
- 23 23 25 25
 Compd
 No.
Ik
Il
Im
In
Io
Ip
Iq
Ir
Is
It
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 23 23 25 25
- 20 20 22 22
- 19 21 24 25
- 18 20 23 25
- 20 22 23 25
- 19 21 23 23
- 20 22 25 27
- 22 25 25 25
- 18 20 22 23
- 18 19 22 25
                  A. niger MTCC-282                                               A. clavatus MTCC-227
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
Griseofulvin
Nystatin
Im Is
Iq It
Ir
Is
It
Ik Ik Ik Ip Ik Ir
Ir Io Il Iq ImIt
Iq ImIr In
Ir In Is Io
Io It Iq
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”
           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIIa-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 1G : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 3-AMINO-4-SUBSTITUTED PHENYL-5-METHYL-1,4,-
5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-ONES.(Iu-d’).(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 12 13 15 17
- 11 12 15 17
- 12 13 15 21
- 13 14 14 18
- 13 15 17 18
- 13 16 17 19
- 11 14 15 18
- 12 14 18 21
- 09 13 15 19
- 12 15 18 21
 Compd
 No.
Iu
Iv
Iw
Ix
Iy
Iz
Ia’
Ib’
Ic’
Id’
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 14 16 18 21
- 15 18 19 20
09 10 13 14 15
- 15 16 17 19
- 12 15 16 18
- 12 14 15 17
- 13 16 17 19
- 10 13 15 17
- 11 13 15 16
- 10 15 16 18
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
Ix Iz Ib’ Iw
Iy Id’ Iz
Iz Ib’
Ic’
Id’
Iu Iu Ia’ Iu Id’ Iu Ia’
Iv Iv Id’ Iv Iv Id’
Ix Ix Ix Ix
Ia’ Iy Iy Iy
Iz Ia’
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIIa-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 1H : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 3-AMINO-4-SUBSTITUTED PHENYL-5-METHYL-1,4,-
5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-ONES.(Iu-d’).(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
10 15 17 19 22
08 13 14 15 16
- 12 14 15 16
- 15 17 18 18
- 12 15 19 23
- 15 15 18 19
- 14 16 17 18
- 15 17 18 19
- 12 12 14 15
- 12 13 15 15
 Compd
 No.
Iu
Iv
Iw
Ix
Iy
Iz
Ia’
Ib’
Ic’
Id’
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 11 15 18 19
- 10 14 16 18
- 11 12 13 15
12 14 16 18 19
- 11 13 18 21
08 10 13 15 17
- 10 13 15 19
- 09 11 12 13
07 12 15 17 21
- 13 13 15 17
                          E. Coli MTCC-443                                                        P. Aeruginosa MTCC-424
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
Iu Iu Iu Iu
Ix Ix Iy Iy
Iz Ia’
Ib’ Ib’
Iu Iu Iy
Ix Ix Ic’
Ic’ Iy
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIIa-j) with known choosen standard drugs
TABLE NO. 1I : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 3-AMINO-4-SUBSTITUTED PHENYL-5-METHYL-1,4,-
5,7-TETRAHYDRO-6H-PYRAZOLO [3,4-d] PYRIMIDIN-6-ONES.(Iu-d’).(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 20 20 22 22
- 19 21 24 25
- 18 20 23 25
- 20 22 23 25
- 19 21 23 23
- 20 22 25 27
- 22 25 25 25
- 18 20 22 23
- 18 19 22 25
- 21 22 23 25
 Compd
 No.
Iu
Iv
Iw
Ix
Iy
Iz
Ia’
Ib’
Ic’
Id’
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 21 22 23 25
- 19 22 25 25
- 18 18 21 22
- 22 22 24 24
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
- 18 20 22 22
- 21 22 23 25
                 A. niger MTCC-282                                                  A. Clavatus  MTCC-1323
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
Griseofulvin
Nystatin
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
Iu Iu  Iu Iu
Ix Iv  Iv Iv
Iz Ix  Ix Ix
Id’ Id’  Iz Iz
 Ic’ Id’
 Id’
Iu Ia’ Ia’ Iz
Iv Ib’ Ia’
Ix Ic’
Iy Id’
Iz
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PART - II
STUDIES ON PYRIMIDINES
INTRODUCTION
Pyrimidine [26] is a six membered heterocyclic compound consisting
of two nitrogen atoms at 1 and 3 positions of heterocyclic ring.
N
N
 pyrimidine
[26]
Generally pyrimidine derivatives such as 2-hydroxy-substituted-pyrimidine,
2-mercapto-substituted-pyrimidine and 2-amino-substituted-pyrimidine are
studied. Pyrimidines have been isolated from the nucleic acid hydrolysates.
Pyrimidines are among those molecules that make life possible, have
been some of the building blocks of DNA and RNA. Several analogues of
pyrimidines have been used as compounds that interfere with the synthesis
and functioning of nucleic acids e.g. fluorouracil, which has been used in can-
cer treatment. Also there are some thiouracil derivatives, which produce ad-
verse reduction in susceptible patients and found more potent and less likely
to produce side effects and is being widely used87. There are several other
important groups of pyrimidines with medicinal uses.
Pyrimidine ring carrying various substituents may be built up from two
or three aliphatic fragments by the principle synthesis or by a variety of other
syntheses, which are complimentary rather than alternative to it. An alternative
method of synthesis is the isomerisation or break down of another hetero-
cycles such as    hydration of purine, but such methods are rarely used. Pyrimi-
dine is best  considered as a resonance hybrid to which the uncharged equiva-
lent Kekule structures  18 and 18a and charged structures 18b and 18g con-
tributes. The self consistent π (pi) electron densities required for the ground
state of pyrimidine are 0.776, 0.825 and 1.103 for positions 2, 4 and 5 respec-
tively92. Despite considerable localization of π (pi) electrons at nitrogen atoms
of pyrimidines the ring system is still sufficiently aromatic to possess substan-
tial stability. This has a great advantage in the primary synthesis of pyrim-
idines.
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The first primary synthesis from aliphatic fragments was carried out by
Frankland et.al., in 1848. Since then a many distinct primary synthetic meth-
ods have been devised81,83-85,89,91,94,96,98,100.  It is also possible to
prepare pyrimidines from other heterocyclic compounds such as pyrrole80,
imidazole84, isoxazole and oxazole88,90, pyridine98, pyrazine99, 1,3,5-tri-
azine93, oxazine95, thiazine101 by different processes.
SYNTHETIC METHODS FOR PYRIMIDINES
Various methods for synthesis of pyrimidines  which are reported in the
literature are as follows.
(a) By the condensation of urea and malonic acid led to formation of pyrimi-
dine104.
(b) By the condensation of malonic ester and urea led to formation of pyrimi-
dine105.
(c) By the condensation of formamidine with phenylazomalononitrile led
to formation of 4,5,6-triaminopyrimidine103.
(d) By the condensation of aromatic aldehydes,ß-ketoester or substi-
tuted ß-ketoester with urea or thiourea led to formation of pyrim-
idines102.
(e) By the condensation of thiourea and substituted ß-ketoester in pres
ence of sodium ethoxide led to formation of 2-mercapto-pyrimidi-
nes106.
(f) By the condensation of chalcones with dicyandiamide in presence
of piperidine led to formation of pyrimidines107.
(g) By thermal or microwave irridiation of thiourea and substituted ß-ketoester
in presence of dimethylformamide led to formation of substituted
tetrahydropyrimidines108.
(h) One pot synthesis of aromatic  aldehydes,ß-ketoester  or sub-
stituted  ß-ketoester  with urea  or thiourea  led to formation of  sub-
stituted  dihydro pyrimidin-2-ones catalysed by CuCl2109.
N
N
N
N
[27a][27] [27b] [27c]
[27d] [27e] [27f]
N
N
N
N
N
N
N
N
N
N
N
N
+ +
+ +
++
[27g]
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(i) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of 3,4-dihydro
pyrimidin-2-(1H)-ones/thiones under microwave irradiation110.
(j) One pot synthesis of aromatic aldehydes,ß-ketoester or substi
tuted ß-ketoester  w i th  urea  o r  th iourea  led  to  format ion o f
dihydropyrimidin-2-(1H)-ones catalysed by Tin (II) chloride
(SnCl2) 110.
(k) One pot synthesis of aromatic aldehydes,ß-ketoester or substituted
ß-ketoester with urea or thiourea led to formation of 3,4-dihydro
pyrimidin-2-(1H)-ones by microwave induced eco-friendly solvent free
biginelli reaction catalysed by calcium chloride111.
MECHANISM
PATH - A
X = O, S & NH.
The present work is explained by considering basic mechanism of
multicomponents biginelli reaction. This includes the condensation of substi-
tuted aldehydes (a) with either urea or thiourea or guanidine to form hemiaminal
(b) with some similarities to the mannich condensation. Hemiaminal (b) un-
dergoes dehydration in presence of acid catalyst to produce iminium cation
(c) as a intermediate. The enamine (iminium cation) (c) generated acts as an
electrophile for the nucleophilic addition of keto enol of 4-methyl-oxo-N-
O
H
H+
H
OH+
H
OH
+
NH2
NH2
X
H+
NH
OH
H
NH2
X
NH
XNH2
+
-H2O
H+
(a)
(b) (c)
(d) (e)
NH
N
H
X
H
CH3
O
NHN
OHCH3
O
NHN
OCH3
O
NHN NH
XNH2
H
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phenylpentanamide with removal of proton to produce (d). The intermediate
(d) undergoes intramolecular condensation in presence of acid between oxy-
gen of ketone and amino group of urea or thiourea or guanidine to give the
cyclised targeted product (e).
PATH - B
O
H H+ H
OH+
H+
-H2O
NH
N
H
X
H
CH3
O
NHN
H
OH
+
NH2
NH2
X
..-H2O -H+
H+
[a] [b]
[c]
[d]
[e] [f]
OCH3
O
NHN
H
:
O+CH3
O
NHN
H
OH
H
O+CH3
O
NHN
H
H
OCH3
O
NHN H
+
..
NH
NH2
X
OCH3
O
NHN
X = O, S & NH.
This mechanism includes the condensation of substituted benzaldehydes
[a] with keto enol of 4-methyl-3-oxo-N-phenylpentanamide [b] to form
intermidiate [c] with some similarities to the aldol condensation. Intermidiate
[c] udergoes dehydration in presence of acid catalyst to produce arylidine
[d]. The condensation of arylidine [d] with either urea or thiourea or guanidine
to form hemiaminal intermidiate [e]. Hemiaminal intermidiate [e] undergoes
intramolecular condensation in presence of acid between oxygen of ketone
and amino group of urea or thiourea or guanidine to give cyclised targeted
product [f].
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PHARMACOLOGICAL IMPORTANCE OF PYRIMIDINES
Numerous pyrimidines are well known drugs for variety of diseases. They
may be placed in four categories viz. barbiturates, sulfonamides, antimicrobi-
als and antitumor agents. Uracil, thymine, alloxan, vicine and divicine, cytosine,
chroticacid, willardiline, tetradotoxine, becimethrian [28], blasticidine [29],
cougerotin, amicetin, bamicetin and plicacetin, phleomicine, blemycin and re-
lated families [30].
N
N
NH2
HOH2C
OCH3
NN O COOH
NH
NH2
NH2
NH
CH3
O
O
N
N
NH2
CH3
O
NH
R2
R1
[28]          [29]         [30]
Pyrimidine derivatives have wide varieties of usages. Pyrimidine ring
system is also present in Vitamin B2 and folic acid. Pyrimidine ring system
having a mercapto group occupy a unique position in medicinal chemistry.128
These types of derivatives play a vital role in biological processes114-116 as
well as synthetic drugs.113
Some of the therapeutic activities of pyrimidine derivatives can be
summarized as follows.
[a] Antithyroid126,127 [b]      Antitumor119,148-149
[c]      Antihypertensive129,140-141  [d]      Antiinflammatory1139,175-176
[e]      Diuretic118 [f]       Antimalarial120,122,125
[g]      Antispasmodic121 [h]      Anticonvulsant150
[i]       Antineoplastic130,168 [j]       Anthelmintic134
[k]      Antimicrobial117,131-135,142,151-174
[l]       Cardiovascular143-145 [m]     Antiviral136,165-168
[n]      Platelet aggregation inhibitor123,124
[o]      Antihistamine137,138 [p]      Anti-HIV146,177
[q] Antitubercular147
The basis of any rational drug discovery programme is fundamently, the
Medicinal Chemistry. Although the synthesis of modified nucleic acids has been
a subject of interest for some time, the intense focus on the medicinal chemis
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try of oligonucleotides dates perhaps to not more than five years. As a result
of this, the scope of medicinal chemistry has recently been expanded enor-
mously, but the biological data of supporting the conclusions about synthetic
strategies have just begun to emerge.
Modifications in the base, sugar and phosphate moeities of oligonucle-
otides and oligonucleotide conjugates have been reported. The subjects of
medicinal chemical programmes include approaches to create enhanced af-
finity and more selective  affinity for RNA or duplex structures, the ability to
cleave nucleic acid targets, enhanced nuclease stability, cellularuptake and
distribution, in vivo tissue distribution, metabolism and clearance. Although
substantial progress in the    medicinal chemistry of oligonucleotides has been
made in the past three years, it is not yet possible to reach the conclusion
about the therapeutic ability of the novel modifications. Preliminary data on
effects on nuclease stability and hybridization properties for a few modifica-
tions and activity in vitro suggest that the next generation of oligonucleotides
may display substantially improved potencies and   selectivity.
PYRIMIDINE MODIFICATIONS (Nucleotide)
A relatively large number of modified pyrimidines have been synthe-
sized and now incorporated into oligonucleotides and evaluated. The principle
sites of modification are C-2, C-4, C-5 and C-6 [31].  These and other
nucleoside analogues have recently been thoroughly reviewed.203
N
N
NH2
1
3
4
5
6
C-5C
C-6
C-4C-4
C-2 2
Sites of Pyrimidine Modification
[31]
In as much as the C2 position is involved in Watson-Crick hybridization,
oligonucleotides containing C2 alkyl modified  pyrimidines have shown unattrac
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tive hybridization characters. However, an oligonucleotide containing 2-thioth-
ymidine [32] was found to hybridize well to DNA and, in fact even better to
RNA with a thermal melting temperature (ΔTm) value of 1.5°C/modification. In
a different study, oligoribonucleotides with 2’-o-methyl-2-thiouridine [33] ex-
hibited a thermal melting temperature (ΔTm) value of +5.5°C/modification
when hybridized against RNA resulting from a highlly preoganized RNA-like
C3’-endo conformation (attributed to the combination of 2-thio modification
and 2’-o-Me-substituent). Oligonucleotides with this modification also exhibit
better hybridization discrimination for the wobble uracil-guanosine (U-G) base
pair formation compared to the normal uracil-adenine (U-A) base pair. This
selectivity is a result of weaker    hydrogen bonding and increased steric bulk
of the 2-thiocarbonyl group.201
NH
N
O
S
CH3
O
O
O
CH3
CH3
NH
N
O
S
CH3
O
O
O
CH3
CH3
O
CH3
[32] [33]
In contrast, the pyrimidine modifications in 4-position with interesting
properties have been reported. 4-Thiopyrimidines [34,35] have been incorpo-
rated in to o l igonucleot ides wi th  no s ign i f icant  negat ive ef fect  on
hybridization.However,    recent studies have shown destabilization in the nor-
mal uracil-adenine (U-A) base pair formation and stabilization of the wobble
uracil-guanosine (U-G) base pair for 4-thiouridine. A bicyclic and an 4-methoxy
analog of cytosine were shown to hybridize with both purine bases in DNA with
thermal melting temperature (Tm) values approximately equal to that of natu-
ral base pairs.  Additionally, a fluorescent base has been incorporated into
oligonucleotides and shown to enhance DNA-DNA duplex stability.202
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NH
N
O
S
CH3
O
O
O
CH3
CH3
NH
N
O
S
CH3
O
O
O
CH3
CH3
OH
[34]          [35]
The pyrimidine modification at C5 position including halogenated
nucleosides have been reported. Although the stability of duplexes may be
enhanced by incorporation 5-halogenated uracil containing nucleosides, the
occasional mispairing with guanidine and the potential that the oligonucleotide
might degrade and release toxic nucleosides analogs cause concern. Oligo-
nucleotides containing 5-propynylpyrimidine [36,37,38] modification have been
shown to enhance the duplex stability thermal melting temperature (ΔTm = 1.6°C/
modification ), and support RNase H activity. The 5-heteroaryl-pyrimidines were
also shown to increase the stability of duplexes. A more dramatic influence was
reported for the tricyclic 2’-deoxycytidine analoges, termed phenoxazine, ex-
hibiting an enhancement of  2-5°C/modification, depending on the positioning
of the modified bases.191
N
N
NH2
O
O
O
O
CH3
N
N
NH2
O
O
O
O
CH3
NH
N
O
O
O
O
O
CH3
[36]          [37]          [38]
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As expected, modifications in the C6 position of pyrimidines are highly
dupled destabilizing. Oligonucleotides containing 6-azapyrimidines [39] have
been shown not only to reduce the  thermal melting temperature (Tm) value by
1-2°C per modification, but also to enhance the nuclease stability of oligonucle-
otides and to support E. coli RNase H-induced deradation of RNA targets.204
N
N O
O
O
O
NH
O
O
N+
H
H
H
[39]
PYRIMIDINE MODIFICATIONS (Non-nucleotide)
The increasing interest in the early 1970s in properties and use of inter-
feron (IFN) together with the difficulty in producing useful amounts of interferon
(IFN) led to the search for agents that would induce IFN in the host.
Precedenced at that time for interferon (IFN) inducers included viruses and bacte-
rial wall constituents and entities of large molecular weight such as the poly-
nucleotides. There were also several examples of low molecular weight substances
such as certain antibiotics and the antiviral agent, tilorone.187 In 1976 it was re-
ported that 6-methyl pyrimidinone(2-amino-5-bromo-6-methyl-4-(3H)pyrimidinone,
ABMP) induced circulating levels of interferon (IFN) in several animal specis upon
oral or intraperitoneal administration.182 Subsequent structure-activity studies
yielded a more potent and less toxic 6-phenyl ananlog called ABPP or bropirimine
(2-amino-5-bromo-6-phenyl-4-(3H)pyrimidinone) (figure 1 and Table 1).180,182
Bropirimine and related 6-aryl analogs were examined extensively for efficacy
in virus and tumor models, along with their immunomodulatory properties and
overall pharmacological effects.192
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OH,NH2,NR2,N3,Cl,H,NHCH2CH2OH,OCH2CH2NH2
5
6
4
N
1
N
3
2
Me,Et,Pr F,Cl,Br,I,Et,MeCH=CH2,
Prn,CHCCH2;CN.CO2Et,
MeCH2OCH2CH2,NO2,
H,Ph,CH2Ph,CH2SiMe3
NH2,RCONH2,Me2N,O2NNH,
Me2NCH=N,CHONH,OH,
H2NC(=NH)NH N-OH
Alkyl,aryl,heteroaryl
 Figure 1 : Preliminary SAR of antiviral activity of pyrimidinones
    Table - I
Antiviral Activity
monosubstituted Disubstituted       Heterocyclic
Active         2-F,OMe, Me 3,5-OMe 1-Naphthyl
          3-F,OMe, Cl, NO2 2,5-Cl2 2-Pyrazyl
Me, CF3, MeCH2CH2O, 3,5-OMe 2,3-pyridyl
Br,I 3,4-Cl2 2-Furyl
4-F, Cl 3,5-Cl2
Inactive 4-Me, CN, Butyl, 2,3-OMe 2-Napthyl
OH,OCH2ph, OMe 1-Furyl
4-Pyridyl
                                         2-Quinoline
As with the polynucleotides, the pyrimidinones exhibited significant ac-
tivity against interferon (IFN) sensitive viruses such as Semliki Forest virus in vivo.
However, in addition, they exhibited prophylactic and therapeutic activity upon
either local or systemic administration to rodents infected with a variety of
DNA viruses, such as the herpes viruses (HSV-1, HSV-2 , CMV  and pseudora-
bies), and when administered intranasally for upper respiratory infections, such
as infectious    bovine rhinortacheites, influenza A and para-influenza-3. Par-
ticularly interestion activity was noted  with bropirimine on intravaginal admin-
istration in protection against HSV-2 intravaginal infection in guinea pigs, an
important model for genital herpes in humans.193 Bropirimine also exhibited
activity when given either intraperitoneally or orally to mice infected with Listera
monocytogenes. The efficacy in this model  was not abrogated by the addition
of anti-interferon (IFN)  antibody.188
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PYRIMIDINES AS ANTITUMOUR AGENTS
A number of other pyrimidine antagonists displaying antitumour activ-
ity, in which the base is conjugated to a modified suger ring have been re-
ported. Although D-Arabinofuranosyl uridine (ara-uridine) shows no useful
acitivity,  and 5-bromo- and 5-iodo-D-arabinofuranosyl uridine inhibit the growth
of  sarcoma 180 and L1210 cells in culture.179 Other thymidine analogues with
simi lar  act iv i ty  i n c l u d e  5 - a z i d o m e t h y l - , 5 - a m i n o m e t h y l  a n d  5 -
hydroxymethyl-2’-deoxyu-ridine181. 3’-Amino-3’-deoxy thymidine183 and 3’-
amino-2’,3’-dideoxycy-tidine184 also posses strong activity against L1210 leu-
kaemia 2’-Deoxy-2’-fluoro-5-methyl-1-B-D-arabinofuranosyluracil (FMAU; 40)
is highly active against arabinofuranosyl cytidine (ara-C) resistant L1210 and P815
cell lines both in vitro and in vivo.190 2-B-D-Ribofuranosylthiazole-4-
carboxamide (Tiazofurin; 41) has aroused much interest recently for its activ-
ity against solid tumour such as lung carcinoma. It is metabolized to an ana-
logue of NAD in which the thiazole-4-carboxamide moiety replaces the nicoti-
namide ring. However, it also depresses the synthesis of DNA and RNA, and
thus merits inclusion as an antagonist of normal purine and pyrimidine me-
tabolism.189
N
N
O
O
H CH3
O
OH
OH
F
S N
CONH2
O
OH
OH OH
[40]       [41]
PYRIMIDINES AS ANTI-HIV AGENTS
The strategy of designing nucleoside analogs that are selective for vi-
ral DNA polymerases is the most well-studied and successful approch to
viral chemotherapy, and has led to the discovery of several clinically useful
antiviral drugs. This strategy, however, has inherent limitations. Human DNA
polymerases also required dNTP’s and the chemical mechanisms of polymer-
ization by the viral and human enzymes are similar. Nucleoside analogs often
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have significant host toxicity that is probably related to inhibition of host cell DNA
synthesis. Nevertheless, these compounds constitute the major class of antivi-
ral drugs, and this approach is likely to yield additional active compounds in
the near future. For the long term, however, other strategies may ultimately lead
tonmmore selective agent withn lower toxicity.
Obviously, the key to design analogue with a lower affinity for the host en-
zyme than the viral enzyme, which requires that there be structural differences
between the enzyme active sites. For reverse transcriptase, the most well stud-
ied inhibitor is 3’-azido-3’-deoxythymidine (AZT; 42), which is currently used
clinically to treat AIDS.212,213
N
NH
O
CH3
O
OH
N3
O
(42)
3’-azido-3’-deoxythymidine (AZT) inhibits HIV reverse transcriptase with
an IC50 of 40nM195, but is 100-300 times less active against mammalian
DNA polymerase α and DNA polymerase γ. The reason for this selectivity is
not clear since 3’-azido-3’-deoxythymidine (AZT) is a chain terminator for mam-
malian DNA polymerases and inhibits normal cellular DNA synthesis.185 Sev-
eral other dideoxynucleoside analogs have been shown to be potent inhibi-
tors of HIV replication in vitro.196,200 In general, these compounds have the same
mechanism of action as 3’-azido-3’-deoxythymidine (AZT), that is, intracellular
conversion to the triposphate derivative and subsquent inhibition of HIV re-
verse transcriptase.
Some of these compounds are simply analogs of the nautral 2’-deoxy-
nucleoside in which the 3’-OH group has been replaced with a hydrogen, such
as 2’,3’-dideoxycytidine[43], 2’,3’-dideoxyadenosine[44] and 2’,3’-dideo-
xythymidine [45]. Other analogs contain a 2’-3’ double bond, such as 2’3’-
didehydro-2’,3’-dideoxythymidine [46]. Several related analogs with other
modifications to the ribose ring or the heterocyclic base moiety have also been
reported to have activity against HIV or HIV reverse transcriptase.197,198
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N
NH
NH2
O
O
OH N
N
N
N
NH2
O
OH N
NH
O
O
O
OH
CH3
N
NH
O
O
O
OH
CH3
             [43]              [44]                [45]             [46]
R. A. Nugent et. al.,205 have synthesized pyrimidine thioethers [47]
and evaluated for inhibitory properties against wild-type HIV-1 reverse tran-
scriptase.
N
NH
CH3
OH
S
(CH2)n
R1
R2
R1= 2,6-(Cl)2, 4-F
R2=4-OCH3,4-NO2, 4-CN, 4-Br
[47]
A family of trisubstituted pyrimidines has been described as selective
COX-2 inhibitors. To explore the usefulness of pyrimidine derivatives as potential
NSAIDs. Aurelio Orjales et. al.,206 have synthesized novel pyrimidine deriva-
tives [48] and [49].
In vitro biological evaluation of these compounds has provided infor-
mation to determine the structural features necessary for COX-2 inhibitory ac-
tivity.
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Z
X
Y
R
S
R1
MeO2S
N
N NH
MeO2S
CH3 CH3
[48] Y = CH; X, Z = N      [49]  Y, Z = N; X = CH
F. Manetti et. al.,207 have synthesized novel pyrimidines [50] with
nanomolar activity toward recombinant HIV-1 and mutant HIV-1 strains.
N
NNH2
Cl
S R
R = Ph, Me, CO2Me,     
       CONMe2, CONEt2
[50]
D.Rot i l i  e t  a l . ,208  have synthes ized 6-subst i tu ted- [1- (2 ,6-
difluorophenyl]pyrimidinones [51,52] and tested against endogenous,
nontelomeric reverse transcriptase (endo-RT) in human differentiating cell
systems to investigate their antiproliferative and cytodifferentiating activity.
N
NH
O
S
CH3
CH3
FF
N
NH
O
N
CH3
CH3
FF
CH3
CH3
[51] [52]
R. Stoorer et al.,209 have synthesized 3-substituted-6-(3-ethyl-4-
methylanilino)uracils [53,54] screened for their capacity to inhibit the replica-
tion-specific bacterial DNA plymerase IIIC (pol IIIC) and the growth of Gram+
bacteria in culture.
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N
H
N
O
O NH
CH3
CH3
(CH2)n
OH
N
H
N
O
O NH
CH3
CH3
(CH2)n
OMe
[53]   n = 2,3,4. [54] n = 2,3,4.0
A.Or ja les  e t  a l . ,210  have synthes ized new ser ies  o f  2- (4-
methylsulfonylphenyl)and 2-(4-sulfamoylphenyl)pyrimidines [55] and evaluated
for their ability to inhibit cyclooxygenase-2 (COX-2).
N
NX
R2
R3
R4
R5
SO2R1
[55]
Recently, Y.Miyazaki et al.,211 have synthesized 4-amino-5,6-furo [2,3-d]
pyrimidines [56] and identified as inhibitors of glycogen synthase kinase-3B (GSK-
3B).
N
N
O N
NH S
OO
NH2
[56]
In view of procuring highly potent biodynamic agents and after review-
ing recent literature survey on oxo / thioxo / iminopyrimidines for their  various
methods of synthesis and different pharmacological activities, synthesis of py-
rimidines have been undertaken which can be summarized in the following
sections as follows:
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SECTION  - II : PREPARATION AND BIOLOGICAL EVALUATION OF 1- 2-
IMINO / THIOXO / OXO- 6-METHYL-4-PHENYL-1,2,3,4-
TETRAHYDROPYRIMIDIN-5-YL)-ETHANONES.
SECTION  - III : PREPARATION AND BIOLOGICAL EVALUATION OF 6-ME
THYL-2-OXO / THIO / IMINO -4-SUBSTITUTED PHENYL-
N-(PYRIDIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDES.
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SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 1-[2-IMINO/THIOXO/
OXO-4-(4-SUBSTITUTEDPHENYL)-6-METHYL-1,2,3,4-TETRAHYDRO-
PYRIMIDIN-5-YL]- ETHANONES.
Keeping in view of wide spectrum biodynamic activities116-174 of pyrim-
idines and with a view to have potent therapeutic agents, the synthesis of 1-[2-imino-
4-(4-substituted phenyl)-6-methyl-1,2,3,4-tetrahydropyrimidin-5-yl]-ethanones
(IIa-j) have been synthesized by the condensation of different substituted
benzaldaldehydes, acetyl acetone and guanidine hydrochloride / N-methyl urea
/thiosemicarbazide in the presence of conc. acid.
(IIa-j)
R = Substituted Phenyl    R1= H/CH3/NH2     X = O / S / NH
The constitution of the products (IIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and P. Aeruginosa MTCC-424(Gram positive) and E. coli MTCC-443 and
(Gram negative) bacterial strain and antifungal activity towards Aspergil-
lus niger  MTCC-282 and A. Clavatus MTCC-1323 at different concentra-
tions  : i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum
Inhibitory  Concentration) values. The biological activities of the synthesized
compounds (VIIa-j) were compared with standard drugs viz., Amoxicillin,
Chloramphenical, Sparfloxacin, Ciprofloxacin, Griseofulvin and Nysta-
tin.
N
N
H
X
CH3
O
CH3
R
R1
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REACTION SCHEME
(IIa-d’)
R, R1= Substituted Phenyl
N
N
H
X
CH3
O
CH3
R
R1
CH3 CH3
O O
NH
NH2 X
R1
RCHO H+/
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 1-[2-IMINO/THIOXO/
OXO-4-(4-SUBSTITUTED PHENYL)-6-METHYL-1,2,3,4-TETRAHYDROPYRIMIN-
5-YL]-ETHANONES (IIa-d’).
(A) Preparation of 1-[2-imino-4-(4-methoxy phenyl)-6-methyl-1,2,3,4-
tetrahydropyrimidin-5-yl]-ethanone(IIb).
A mixture of  acetyl  acetone  (1 .00 gm,  0 .01M),  4-
methoxybenzaldehyde (1.36 ml, 0.01 M), guanidine (0.88 gm, 0.015 M)
and catalytical amount of conc. acid in ethanol (30 ml)  was heated under re-
flux condition for 8-10 hrs. The reaction mixture was kept at room temperature
for 24 hrs. The yellow crystalline product obtained was isolated and recrystal-
lized from ethanol. Yield : 69 %, M.P. : 204°C, (Required : C, 64.85%; H,
6.61%; N, 16.20% for C14H17N3O2 Found : C, 64.82%; H, 6.62%; N,
16.17%).
TLC  solvent system Rf1  :  Ethyl acetate : Hexane        (3.0 : 7.0)  = 0.43.
TLC  solvent system Rf2   :  Methanol        : Chloroform (0.5 : 9.5)  = 0.68.
Similarly, other compounds (IIa-d’) were synthesized. The physical data
are recorded in Table No. 2a,2b,2c.
(B) Antimicrobial activity of 1-[2-imino/thioxo/oxo-4-(4-substituted
phenyl)-6-methyl-1,2,3,4-tetrahydropyrimidin-5-yl]-ethanones(IIa-d’).
Antimicrobial activity testing was carried out as described in part - I,
section - I, page No. 27. The MIC values of test solution are recorded in
Table No. 2A,AB,2C,2D,2E,2F,2G,2H,2I.
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IR  SPECTRAL  STUDY  OF   1-[2-IMINO-4-(4-METHOXY PHENYL)-6-ME-
THYL-1,2,3,4-TETRAHYDROPYRIMIN-5-YL]-ETHANONE (IIb).
Aromatic and
ring skeletal
vibration
Pyrimidine
Moiety
Subtitution
pera(-4-)
substituted
Frequency in cm-1
Observed Reported
Reference
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   780
1690 - 1650
3300-3700
1650 - 1550
800 - 600
810 - 880
Type  Vibration  mode
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C=N  (str., v)
N-H (str., m)
N-H (def., s,m)
C-O (str., s)
C-H (def., v,s)
3037.57
1461.19
1101.19
798.56
1652.09
3683.20
1652.09
662.57
828.21
311
309
311
311
312
312
309
311
309
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
NH
N
H
CH3
CH3
O
O
CH3
NH
(IIb)
8 3Part  -  II           “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
-NH2
Aromatic and
ring skeletal
vibration
Pyrimidine
Moiety
Subtitution
pera(-4-)
substituted
Frequency in cm-1
Observed Reported
Reference
3300-3700
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   780
1690 - 1650
3300-3700
1650 - 1550
800 - 600
810 - 880
Type  Vibration  mode
N-H (str., v)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C=N (str., v)
N-H (str., m)
N-H (def., s,m)
C-O (str., s)
C-H (def., v,s)
3650.41
3044.93
1540.21
1125.26
820.60
1675.11
3679.34
1550.21
692.47
824.61
311
312
312
312
312
309
309
309
311
309
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
IR  SPECTRAL  STUDY  OF   1-[3-AMINO-4-(4-METHOXY-PHEYNYL)-6-ME-
THYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIN-5-YL]-ETHANONE(IIl).
N
N
H
CH3
CH3
O
O
CH3
S
NH2
(IIl)
8 4Part  -  II           “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
Aromatic and
ring skeletal
vibration
Pyrimidine
Moiety
Subtitution
pera(-4-)
substituted
Frequency in cm-1
Observed Reported
Reference
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   780
1690 - 1650
3300-3700
1650 - 1550
800 - 600
810 - 880
Type  Vibration  mode
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C=N  (str., v)
N-H (str., m)
N-H (def., s,m)
C-O (str., s)
C-H (def., v,s)
3624.31
1501.49
1150.83
799.52
1653.05
3659.69
1653.05
666.43
827.25
311
312
309
312
311
310
309
311
311
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
IR  SPECTRAL  STUDY  OF  5-ACETYL-4-(4-METHOXY- PHENYL)-3,6-
DIMETHYL-3,4-DIHYDROPYRIMIN-2(1H)-ONES (IIv).
N
N
H
CH3
CH3
O
O
CH3
O
CH3
(IIv)
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PMR  SPECTRAL  STUDY  OF  1-[2-IMINO-4-(4-METHOXY-PHENYL)-6-
METHYL-1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL]-ETHANONE (IIb).
Serial
No.
Signal Position
(δ ppm)
Relative No.
of Protons
Multiplicity Inference
1
2
3
4
5
6
7
singlet
singlet
singlet
doublet
doublet
singlet
singlet
- (CH3)(a)
- NH(b)
- CH(c)
- Ar-H(d,d’)
- Ar-H(e,e’)
- (CH3)(f)
- (CH3)(g)
1.6187
2.0050
5.4369
6.7693-6.7901
6.4695-6.4919
3.8576
2.5976
3H
2H
1H
2H
2H
3H
3H
NH
N
H
NH
O
CH3
O
CH3
CH3
a
b
b
c
dd'
ee'
f
g
(IIb)
8 6Part  -  II           “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
PMR  SPECTRAL  STUDY  OF  1-[3-AMINO-4-(4-METHOXY-PHEYNYL)-6-
METHYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIN-5-YL]-ETHANONE (IIl).
Serial
No.
Signal Position
(δ ppm)
Relative No.
of Protons
Multiplicity Inference
1
2
3
4
5
6
7
8
singlet
singlet
singlet
doublet
doublet
singlet
singlet
singlet
- (CH3)(a)
- NH(b)
- CH(c)
- Ar-H(d,d’)
- Ar-H(e,e’)
- (CH3)(f)
- (NH2)(g)
- (CH3)(h)
1.7157
2.1153
5.5569
6.6749-6.6964
6.4679-6.4896
2.5976
2.0367
3.8496
3H
1H
1H
2H
2H
3H
2H
3H
N
N
H
S
O
CH3
O
CH3
CH3
NH2
a
b
gc
dd'
ee'
f
h
(IIl)
8 7Part  -  II           “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
PMR  SPECTRAL  STUDY  OF  5-ACETYL-4-(4-METHOXY- PHENYL)-3,6-
DIMETHYL-3,4-DIHYDROPYRIMIN-2(1H)-ONES (IIv).
Serial
No.
Signal Position
(δ ppm)
Relative No.
of Protons
Multiplicity Inference
1
2
3
4
5
6
7
8
singlet
singlet
singlet
doublet
doublet
singlet
singlet
singlet
- (CH3)(a)
- NH(b)
- CH(c)
- Ar-H(d,d’)
- Ar-H(e,e’)
- (CH3)(f)
- (CH3)(g)
- (CH3)(h)
1.8556
6.0070
5.7179
6.3928-6.4128
7.4519-7.4719
2.1951
2.9369
3.9415
3H
1H
1H
2H
2H
3H
3H
3H
N
N
H
O
O
CH3
O
CH3
CH3
CH3
a
b
c
dd'
ee'
f
g
h
(IIv)
8 8Part  -  II           “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
M
A
S
S
  S
PE
C
TR
A
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 S
TU
D
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 O
F 
  1
-[2
-IM
IN
O
-4
-(4
-M
ET
H
O
XY
PH
EN
YL
)-6
-M
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H
YL
-1
,2
,3
,4
-T
ET
R
A
H
YD
R
O
PY
R
IM
ID
IN
-5
-Y
L]
-
ET
H
A
N
O
N
E 
(II
b)
.
(II
b)
N
H
N H
C
H
3
C
H
3O
O
N
H
C
H
3
8 9Part  -  II           “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
NH
N
H
CH3
CH3
O
NH
NH
N
H
CH3
CH3
O
O
NH
CH3
NH
NH2 NH2
NH
N
H
O
CH3
CH3
CH3
O
O
CH3
m/z = 206
m/z = 229
N
N
H
CH3
CH3
O
NH
m/z = 151(M+1)
m/z = 193(M+1) m/z = 151(M
+1)
N
N
CH3
CH3
O
m/z = 136(M+1)
NH
N
H
CH3
CH3 NH
m/z = 125(M+2)
m/z = 259
(IIb)
9 0Part  -  II           “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
M
A
S
S
  S
PE
C
TR
A
L 
 S
TU
D
Y 
 O
F 
  1
-[3
-A
M
IN
O
-4
-(4
-M
ET
H
O
XY
-P
H
EY
N
YL
)-6
-M
ET
H
YL
-2
-T
H
IO
XO
-1
,2
,3
,4
-
TE
TR
A
H
YD
R
O
PY
R
IM
IN
-5
-Y
L]
-E
TH
A
N
O
N
E  
(I
I l)
.
(II
l)N N HO
C
H
3
C
H
3
C
H
3O
N
H
2
S
9 1Part  -  II           “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
NH
N
H
O
CH3
CH3
CH3
O
S
NH
N
H
O
CH3
CH3 S
N
N
H
O
CH3
CH3
CH3
O
NH2
SN
N
H
O
CH3
CH3
CH3
O
NH2
S
N
N
H
O
CH3
CH3
CH3
O
NH2
S
N
N
CH3
O
m/z = 291
m/z = 291m/z = 291
m/z = 236
m/z = 276(M+2)
O
CH3
CH3
CH3
O
O
m/z = 217(M+2)
m/z = 198(M+2)
N
N
H
CH3
CH3
O
NH2
S
m/z = 185(M+2)
N+
N
CH3
CH3
O
NH2
m/z = 186(M+1)
(IIl)
9 2Part  -  II           “  Studie s  on  some  nove l  b ioact ive  synthet i c  compounds .”
M
A
S
S
  S
PE
C
TR
A
L 
 S
TU
D
Y 
 O
F 
  5
-A
C
ET
YL
-4
-(4
-M
ET
H
O
XY
- P
H
EN
YL
)-3
,6
-D
IM
ET
H
YL
-3
,4
-D
IH
YD
R
O
PY
R
IM
IN
-2
(1
H
)-O
N
ES
(II
v)
.
(II
v)
N
N HO
C
H
3
C
H
3
C
H
3O
C
H
3
O
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N
N
H
O
CH3
CH3
CH3
O
CH3
O
N
N
H
O
CH3
CH3
CH3
O
O
N
N
O
CH3
CH3
CH3
O
N
N
O
CH3
CH3
CH3
O
N
N
O
CH3
CH3
CH3
N+
N
O
CH3
CH3
N
N
O
CH3
m/z = 274
m/z = 242
m/z = 230(M+2)
m/z = 201(M+1)
m/z = 258
m/z = 216
m/z = 168
N
N
H
CH3
CH3
O
CH3
O
m/z = 186(M+1)
N+
N
CH3
CH3
O
CH3
m/z = 151(M+2)
(IIv)
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”
           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ia-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 2A : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 1-[2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-1,2,3,4-
TETRAHYDROPYRIMIDIN-5-YL]ETHANONE(Ia-j). (Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 12 14 15 19
- 10 15 17 18
- 14 15 17 17
- 12 13 15 18
- 12 14 17 20
- 11 14 18 17
- 12 13 14 17
- 10 14 15 21
- 10 12 15 18
- 12 13 15 17
 Compd
 No.
IIa
IIb
IIc
IId
IIe
IIf
IIg
IIh
IIi
IIj
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 12 14 15 16
- 10 13 14 15
- 12 14 15 16
-   8 11 12 13
- 11 12 15 17
- 10 15 16 18
- 11 14 15 16
-   9 13 15 16
-   9 11 16 17
- 10 14 17 18
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
IIc IIf IIa
IIe
IIh
IIa IIf IIf
IIc IIi IIj
IIf IIj
IIg
IIj
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ia-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 2B : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 1-[2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-1,2,3,4-
TETRAHYDROPYRIMIDIN-5-YL]ETHANONE (Ib). (Ia-j). (Different Inhibition Concentration in μg/ml).
5 25 50 100 250
10 17 18 21 27
- 13 13 15 17
- 11 11 14 15
- 12 13 15 15
- 17 18 18 19
- 13 13 15 17
- 11 11 14 15
- 15 15 17 18
-   9 12 18 18
- 10 13 15 15
 Compd
 No.
IIa
IIb
IIc
IId
IIe
IIf
IIg
IIh
IIi
IIj
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 10 11 14 15
- 13 15 18 19
- 11 12 13 15
- 11 13 13 15
- 15 17 19 22
- 11 12 15 16
- 12 14 17 21
- 10 14 15 16
-   7 11 14 15
- 13 14 16 17
                          E. Coli MTCC-443                                                        P. Aeruginosa MTCC-1688
 Amoxiciline
 Chloramphenicol
 Sparfloxacin
 Levofloxacin
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
IIe IIb IIb IIe
IIe IIe IIg
IIa IIa IIa IIa
IIe IIe
IIh
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ia-j) with known choosen standard drugs
TABLE NO. 2C : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 1-[2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-1,2,3,4-
TETRAHYDROPYRIMIDIN-5-YL]ETHANONE (Ib). (Ia-j). (Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 19 22 25 25
- 18 18 21 22
- 22 22 24 24
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
- 18 20 22 22
- 21 22 23 25
- 19 21 22 25
 Compd
 No.
IIa
IIb
IIc
IId
IIe
IIf
IIg
IIh
IIi
IIj
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 19 21 22 25
- 18 20 22 23
- 18 19 22 25
- 21 22 23 25
- 19 22 25 25
- 18 18 21 22
- 22 22 24 24
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
                  A. niger MTCC-282                                               A. clavatus MTCC-1323
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
Griseofulvin
Nystatin
IIa IIa IIa
IIc
IIe
IIi
IIj
IId IId IIa IIa
IIg IIe IIb IIc
IIi IIg IIc IId
IId IIe
IIe IIg
IIg IIi
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”
           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ik-t) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 2D : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 1-[2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-
1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL]ETHANONE.(IIa-j)(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 11 13 14 17
- 10 13 15 20
- 11 12 15 18
- 12 13 15 17
- 11 12 15 17
- 12 14 15 19
- 12 15 16 21
- 12 14 15 19
- 10 15 17 18
8 12 14 15 17
 Compd
 No.
IIk
IIl
IIm
IIn
Io
IIp
IIq
IIr
IIs
IIt
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 12 14 15 16
- 15 16 17 18
10 11 13 15 17
12 14 16 18 21
- 15 18 19 20
- 10 13 14 15
11 15 16 17 19
- 12 14 16 18
- 12 14 15 17
9 13 16 17 19
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
IIl
IIp
IIq
IIr
IIl
IIn
IIq
IIt
IIk
IIl
IIn
IIo
IIq
IIr
IIs
IIt
IIm
IIn
IIq
IIl
IIn
IIo
IIq
IIr
IIt
IIl
IIn
IIo
IIq
IIr
IIt
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ik-t) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 2E : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 1-[2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-
1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL]ETHANONE.(IIa-j)(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 13 15 16 17
- 15 17 16 17
10 12 13 15 15
- 17 18 18 19
10 14 17 21 25
- 11 11 14 15
- 12 13 15 15
- 17 18 18 19
- 10 14 15 17
- 11 15 17 19
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
8 12 12 13 14
- 13 15 16 17
- 11 13 15 17
-   8 10 12 14
- 13 14 19 23
- 10 12 14 17
- 10 12 13 15
- 10 12 16 18
- 11 13 15 18
- 14 16 18 20
                          E. Coli MTCC-443                                                        P. Aeruginosa MTCC-1688
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
IIl
IIn
IIr
IIl
IIn
IIo
IIr
IIo IIo
 Compd
 No.
IIk
IIl
IIm
IIn
IIo
IIp
IIq
IIr
IIs
IIt
IIl
IIt
IIo
IIt
IIo
IIt
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIa-j) with known choosen standard drugs
TABLE NO. 2F : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 1-[2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-
1,2,3,4-TETRAHYDROPYRIMIDIN-5-YL]ETHANONE.(IIa-j) (Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 18 20 22 23
- 18 19 22 25
- 21 22 23 25
- 19 22 25 25
- 18 18 21 22
- 22 22 24 24
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
 Compd
 No.
IIk
IIl
IIm
IIn
IIo
IIp
IIq
IIr
IIs
IIt
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 18 19 21 22
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
- 18 20 22 22
- 21 22 23 25
- 19 21 22 25
- 18 20 22 23
- 21 23 25 27
                  A. niger MTCC-282                                               A. clavatus MTCC-227
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
Griseofulvin
Nystatin
IIm IIn
IIn
IIp
IIr
IIm IIq IIm IIm
IIq IIt IIp IIq
IIt IIq IIr
IIr IIt
IIs
IIt
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           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIIa-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 2G : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 1-[2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-1,2,3,4-
TETRAHYDROPYRIMIDIN-5-YL]ETHANONE. (IIIa-j). (Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 10 13 15 18
- 12 14 17 20
- 12 14 15 20
- 12 13 14 17
- 12 14 17 21
- 08 12 15 18
- 08 12 14 17
- 11 13 14 17
- 12 13 15 20
- 11 12 15 18
 Compd
 No.
IIu
IIv
IIw
IIx
IIy
IIz
IIa’
IIb’
IIc’
IId’
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 10 13 15 17
- 11 13 15 16
09 12 14 16 18
- 12 15 14 16
- 08 12 13 14
- 09 14 15 16
- 10 11 12 14
- 11 12 15 17
- 14 15 16 18
- 11 14 15 17
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
IIv
IIw
IIy
IIc’
IIc’ IIw IIw IIw
IIx IIc’ IIc’
IIz
IIc’
IIc’
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIIa-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 2H : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 1-[2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-1,2,3,4-
TETRAHYDROPYRIMIDIN-5-YL]ETHANONE. (IIIa-j). (Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 11 14 15 17
08 11 13 17 19
- 17 18 18 19
- 13 14 15 17
- 10 11 14 15
- 11 15 17 18
- 09 13 17 19
08 10 14 15 17
- 13 15 16 17
- 11 15 16 17
 Compd
 No.
IIu
IIv
IIw
IIx
IIy
IIz
IIa’
IIb’
IIc’
IId’
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 10 13 15 16
- 13 15 17 20
- 10 16 17 18
- 11 13 15 16
- 12 13 15 17
- 10 12 14 15
10 13 15 20 22
- 10 11 12 14
- 11 13 13 15
- 12 16 16 18
                          E. Coli MTCC-443                                                        P. Aeruginosa MTCC-424
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
IIw IIw IIv IIa’ IIv
IIw IIa’
IIa’
IId’
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIIa-j) with known choosen standard drugs
TABLE NO. 2I : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 1-[2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-1,2,3,4-
TETRAHYDROPYRIMIDIN-5-YL]ETHANONE. (IIIa-j). (Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 18 20 21 21
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
- 18 20 22 22
- 21 22 23 25
- 19 21 22 23
- 18 20 22 23
- 18 19 22 25
- 21 22 23 25
 Compd
 No.
IIu
IIv
IIw
IIx
IIy
IIz
IIa’
IIb’
IIc’
IId’
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 23 23 25 25
- 20 20 22 22
- 19 21 24 25
- 18 20 23 25
- 20 22 23 25
- 19 21 23 23
- 20 22 25 27
- 22 25 25 25
- 18 20 22 23
- 18 19 22 25
                 A. niger MTCC-282                                                  A. Clavatus  MTCC-1323
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
Griseofulvin
Nystatin
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
IIu IIu IIu  IIv IIu
IIb’ IIy IIw IIx IIw
IIa’ IIy IIz IIx
IIb’ IIa’ IIy
IIb’ IIa’
IIc’ IIb’
IId’ IId’
IIv
IIz
IIa’
IId’
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SECTION - III
PREPARATION AND BIOLOGICAL 4-(SUBSTITUTED PHENYL)-6-ME-
THYL-2-OXO/2-THIOXO/2-IMINO-N-(PYRIDIN-2-YL)-1,2,3,4-TETRA-
HYDROPYRIMIDINE-5-CARBOXAMIDES(IIIa-d’).
Keeping in view of wide spectrum biodynamic activities116-174 of pyrim-
idines and with a view to have potent therapeutic agents, the synthesis of 4-(4-
methoxyphenyl-6-methyl-2-oxo/2-thioxo/2-imino-N-(pyridin-2-yl)-1,2,3,4-
tetrahydropyrimidne-5-carboxamides (IIIa-j) have been synthesized by the con-
densation of different substituted benzaldehydes, acetyl acetone and guanidine
hydrochloride / N-methyl urea / thiosemicarbazide in the presence of conc. acid.
(IIIa-j)
R = Substituted Phenyl      X = O / S / NH
The constitution of the products (IIIa-j) have been delineated by elemental
analyses, IR, PMR and Mass spectral data.
The products (IIIa-j) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442, S. aureus
MTCC-96 and P. Aeruginosa MTCC-424 (Gram positive) and E. coli MTCC-
443 and  (Gram negative) bacterial strain and antifungal activity towards
Aspergillus niger  MTCC-282 and A. Clavatus MTCC-1323 at different con-
centrations  : i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Mini-
mum Inhibitory  Concentration) values. The biological activities of the synthe-
sized compounds (IIIa-j) were compared with standard drugs viz., Amoxicillin,
Chloramphenical, Sparfloxacin, Ciprofloxacin, Griseofulvin and Nysta-
tin.
NH
N
H
X
NH
O
CH3
RN
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REACTION SCHEME
   (IIIa-j)
R =  Substituted Phenyl
X = O / S / NH
NH2
NH2 X
H+
NH
N
H
X
NH
O
CH3
RN
NH
O
CH3
N
O
CHO
+
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 4-(4-SUBSTITUTED)-
6-METHYL-2-OXO/2-THIOXO/2-IMINO-N-(PYRIDIN-2-YL)-1,2,3,4-TETRA-
HYDROPYRIMIDINE-5-CARBOXAMIDES(IIIa-d’).
(A) Preparation of 4-(4-methoxyphenyl-6-methyl-2-oxo/2-thioxo/2-
imino-N-(pyridin-yl)-1,2,3,4-tetrahydropyrimidne-5-carboxamide (IIIb)
A mixture of 3-oxo-N-(pyridin-2-yl)-butanamide (1.78 gm, 0.01M), 4-
methoxybenzaldehyde (1.36 ml, 0.01 M), urea(0.90 gm, 0.015 M) and
catalytical amount of conc. acid in ethanol (30 ml)  was heated under reflux
condition for 8 to10 hrs. The reaction mixture was kept at room temperature
for 24 hrs. The yellow crystalline product obtained was isolated and recrystal-
lized from ethanol. Yield : 77 %, M.P. : 256°C, C18H18N4O3 (Required : C,
64.85%; H, 6.61%; N, 16.56% for C18H18N4O3 Found : C, 64.87%; H, 6.62%;
N, 16.51%).
TLC  solvent system Rf1  :  Ethyl acetate : Hexane        (3.0 : 7.0)  = 0.39.
TLC  solvent system Rf2   :  Methanol        : Chloroform (0.5 : 9.5)  = 0.74.
Similarly, other compounds (IIIa-d’) were synthesized. The physical
data are recorded in Table No. 3a,3b,3c.
(B) Antimicrobial activity of 4-(4-methoxyphenyl-6-methyl-2-oxo/2-
th ioxo/2- imino-N-(pyr id in-2-y l ) -1 ,2 ,3 ,4- tetrahydropyr imidne-5-
carboxamides (IIIa-d’)
Antimicrobial activity testing was carried out as described in part - I,
section - I, page No. 27. The MIC values of test solution are recorded in
Table No. 3A,3B,3C,3D,3E,3F,3G,3H,3I
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Alkane
(methyl)
Aromatic and
ring skeletal
vibration
Pyrimidine
Moiety
Ketone
(Amide)
(Cyclic)
Ether
Para(-4-)
substituted
Frequency in cm-1
Observed Reported
Reference
2975 - 2850
1460 - 1400
1385 - 1300
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   800
1360 - 1310
1340 - 1250
3500 - 3310
1650 - 1550
1740 - 1650
1740 - 1650
1250 - 1200
1050 - 1010
800 - 850
Type  Vibration  mode
C-H (asym. str., m s)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C-N (str., v)
N-H (str., b)
N-H (def., s,m)
C=O (str., b)
C=O (str., b)
Ph-O-C (asym.str., s)
Ph-O-C (sym. str., s)
C-H (def., v,s)
3054.38
1458.23
1324.25
3103.57
1508.38
1117.24
807.60
1344.25
1305.05
3349.08
1651.12
1695.49
1674.27
1207.60
1027.61
827.61
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
310
311
311
309
309
311
312
311
309
311
309
311
312
311
312
309
IR  SPECTRAL  STUDY  OF4-(4-METHOXYPHENYL)-6-METHYL-2-
OXO-N-(PYRIDIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBO-
XAMIDE(IIIb).
NH
N
H
O
NHN
OCH3
O
CH3
(IIIb)
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Alkane
(Dimethyl)
Aromatic and
ring skeletal
vibration
Pyrimidine
Moiety
Ketone
(Amide)
(Cyclic)
Ether
Para(-4-)
substituted
Frequency in cm-1
Observed Reported
Reference
2975 - 2850
1460 - 1400
1385 - 1300
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   800
1360 - 1310
1340 - 1250
3500 - 3310
1650 - 1550
1740 - 1650
1740 - 1650
1250 - 1200
1050 - 1010
850 - 800
Type  Vibration  mode
C-H (asym. str., m s)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C-N (str., v)
N-H (str., b)
N-H (def., s,m)
C=O (str., b)
C=O (str., b)
Ph-O-C (asym.str., s)
Ph-O-C (sym. str., s)
C-H (def., v,s)
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
310
310
311
309
309
312
312
312
311
309
311
311
309
311
311
312
IR  SPECTRAL  STUDY  OF4-(4-METHOXYPHENYL)-6-METHYL-2-
THIOOXO-N-(PYRIDIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDE(IIIl).
2963.72
1434.12
1302.47
3073.67
1507.42
1051.84
819.77
1302.47
1251.84
3410.26
1532.42
1683.91
1681.92
1251.84
1051.43
862.21
NH
N
H
O
NHN
SCH3
O
CH3
(IIIl)
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Alkane
(Dimethyl)
Aromatic and
ring skeletal
vibration
Pyrimidine
Moiety
Ketone
(Amide)
(Cyclic)
Ether
Substitution
Para(-4-)
substituted
Frequency in cm-1
Observed Reported
Reference
2975 - 2850
1460 - 1400
1385 - 1300
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   800
1360 - 1310
1340 - 1250
3500 - 3310
1650 - 1550
1740 - 1650
1740 - 1650
1250 - 1200
1050 - 1010
850 - 800
Type  Vibration  mode
C-H (asym. str., m s)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N-C (str., v)
C-N (str., v)
N-H (str., b)
N-H (def., s,m)
C=O (str., b)
C=O (str., b)
Ph-O-C (asym.str., s)
Ph-O-C (sym. str., s)
C-H (def., v,s)
3080.42
1469.81
1326.89
3022.43
1538.28
1143.83
813.02
1313.02
1213.11
3543.35
1610.61
1689.61
1648.23
1213.11
1148.23
860.82
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
309
309
312
312
312
311
311
309
312
311
309
311
312
311
309
309
IR  SPECTRAL  STUDY  OF2-IMINO-4-(4-METHOXYPHENYL)-6-ME-
THYL--N-(PYRIDIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CAR-
BOXAMIDE(IIIv).
NH
N
H
O
NHN
NHCH3
O
CH3
(IIIv)
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PMR  SPECTRAL  STUDY  OF 4-(4-METHOXYPHENYL)-6-METHYL-2-
OXO-N-(PYRIDIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBO-
XAMIDE(IIIb).
Serial
No.
Signal Position
(δ ppm)
Relative No.
of Protons
Multiplicity Inference
1
2
3
4
5
6
7
8
9
10
singlet
singlet
singlet
doublet
doublet
singlet
triplet
singlet
multiplet
singlet
- (CH3)(a)
- NH2(b)
- CH(c)
- Ar-H(d,d’)
- Ar-H(e,e’)
- NH(f)
- Ar-H(k,i)
-Ar-H(h)
-Ar-H(j)
- (CH3)(g)
2.2482
6.0070
5.6384
7.6514-7.6576
8.0129-8.0339
8.8410
8.1302-8.1517
8.2099
6.9765-7.0099
3.8232
3H
2H
1H
2H
2H
1H
2H
1H
1H
3H
NH
N
H
O
NH
O
N
CH3
O
CH3
a
b
b
c
dd'
ee'
f
g
h
i
j
k
(IIIb)
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PMR  SPECTRAL  STUDY  OF4-(4-METHOXYPHENYL)-6-METHYL-2-
THIOXO-N-(PYRIDIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE- 5-CAR-
BOXAMIDE(IIIv).
Serial
No.
Signal Position
(δ ppm)
Relative No.
of Protons
Multiplicity Inference
1
2
3
4
5
6
7
8
9
10
singlet
singlet
singlet
doublet
doublet
singlet
triplet
singlet
multiplet
singlet
- (CH3)(a)
- NH2(b)
- CH(c)
- Ar-H(d,d’)
- Ar-H(e,e’)
- NH(f)
- Ar-H(k,i)
-Ar-H(h)
-Ar-H(j)
- (CH3)(g)
2.5483
6.0108
5.6493
7.6514-7.6576
8.0114-8.0339
8.8397
8.1517-8.1519
8.2393
6.9765-7.0063
3.8232
3H
2H
1H
2H
2H
1H
2H
1H
1H
3H
NH
N
H
S
NH
O
N
CH3
O
CH3
a
b
b
c
dd'
ee'
f
g
h
i
j
k
(IIIv)
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PMR  SPECTRAL  STUDY  OF2-IMINO-4-(4-METHOXYPHENYL)-6-
METHYL--N-(PYRIDIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDE(IIIv).
Serial
No.
Signal Position
(δ ppm)
Relative No.
of Protons
Multiplicity Inference
1
2
3
4
5
6
7
8
9
10
singlet
singlet
singlet
doublet
doublet
singlet
triplet
singlet
multiplet
singlet
- (CH3)(a)
- NH2(b)
- CH(c)
- Ar-H(d,d’)
- Ar-H(e,e’)
- NH(f)
- Ar-H(k,i)
-Ar-H(h)
-Ar-H(j)
- (CH3)(g)
1.9732
6.0767
5.6108
7.6316-7.6519
8.0319-8.0339
8.8497
8.1371-8.1797
8.2731
6.9663-7.0149
3.8225
3H
2H
1H
2H
2H
1H
2H
1H
1H
3H
NH
N
H
NH
NH
O
N
CH3
O
CH3
a
b
b
c
dd'
ee'
f
g
h
i
j
k
(IIIv)
115P a r t  -  I I   “  Stud i e s  on  some  nove l  b ioact ive  synthet i c  compounds . ”
M
A
S
S
  S
PE
C
TR
A
L 
 S
TU
D
Y 
 O
F 
  4
-(
4-
M
E
TH
O
X
Y
P
H
E
N
Y
L)
-6
-M
E
TH
Y
L-
2-
O
X
O
-N
-(
P
Y
R
ID
IN
-2
-Y
L)
-1
,2
,3
,4
-T
E
TR
A
-
H
Y
D
R
O
P
Y
R
IM
ID
IN
E
-5
-C
A
R
B
O
X
A
M
ID
E
(I
II b
).
(II
I b
)
N
H
N H
N
H
O
O
N
C
H
3
O
C
H
3
116P a r t  -  I I   “  Stud i e s  on  some  nove l  b ioact ive  synthet i c  compounds . ”
N
N
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O
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N
H
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N
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O
CH3
m/z = 338
m/z = 261
m/z = 183(M+1)
m/z = 290
m/z = 246(M+2)
m/z = 219(M+2)
m/z = 162
NH
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NH
O
N
CH3
(IIIb)
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O
CH3
NH
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NHN
CH3 S
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CH3
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m/z = 197(M+1)
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NH
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N
N
H
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N
N
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O
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N
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CH3 O
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NH
N
H
NH
O
N
NHCH3
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N
N
H
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O
O
NH
CH3
CH3
m/z = 258(M+1)
N
N
NHN
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NH
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O
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N
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NH
N
H
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(IIIv)
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           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IVa-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 3A : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 4-(4-METHOXYPHENYL)-6-METHYL-2-OXO-N-(PYRI-
DIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBO-XAMIDE.(IVa-j)(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 12 15 16 18
- 12 14 15 17
- 13 16 17 19
- 10 13 15 17
- 11 13 15 16
- 14 15 16 18
- 12 14 14 16
- 11 13 15 16
- 11 14 15 16
- 10 11 12 13
 Compd
 No.
IIIa
IIIb
IIIc
IIId
IIIe
IIIf
IIIg
IIIh
IIIi
IIIj
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 12 14 17 18
09 13 16 18 19
- 11 14 15 18
- 12 14 17 21
- 12 14 15 19
- 12 15 16 21
- 12 14 15 19
- 11 12 15 18
- 10 12 14 17
- 12 13 15 18
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
IIIb IIIb IIIb IIIb
IIId
IIIe
IIIf
IIIg
IIIc IIIa IIIa IIIa
IIIf IIIb IIIc IIIc
IIIc IIIf IIIf
IIIf
IIIg
Ii
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IVa-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 3B : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 4-(4-METHOXYPHENYL)-6-METHYL-2-OXO-N-(PYRI-
DIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBO-XAMIDE.(IVa-j)(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 11 13 17 19
- 08 12 14 15
09 13 15 16 18
07 12 15 16 17
- 15 17 18 19
08 14 17 18 19
12 13 17 18 21
- 12 14 15 16
11 15 17 18 19
- 12 15 16 19
 Compd
 No.
IIIa
IIIb
IIIc
IIId
IIIe
IIIf
IIIg
IIIh
IIIi
IIIj
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 12 14 16 21
- 10 11 13 14
08 10 13 16 18
08 11 13 15 18
- 10 12 15 18
- 08 11 12 13
- 10 12 14 16
- 09 12 13 15
- 12 13 15 17
- 10 11 13 14
                          E. Coli MTCC-443                                                        B. subtillis MTCC-441
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
IIIe IIIe IIIg
IIIi IIIf
IIIg
IIIi
IIIa
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IVa-j) with known choosen standard drugs
TABLE NO. 3C : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 4-(4-METHOXYPHENYL)-6-METHYL-2-OXO-N-(PYRI-
DIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBO-XAMIDE.(IVa-j)(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 22 25 25 25
- 18 20 22 23
- 18 19 22 25
- 21 22 23 25
- 19 22 25 25
- 18 18 21 22
- 22 22 24 24
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
 Compd
 No.
IIIa
IIIb
IIIc
IIId
IIIe
IIIf
IIIg
IIIh
IIIi
IIIj
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 18 18 19 22
- 18 19 21 22
- 18 20 22 22
- 21 22 23 25
- 19 21 22 25
- 18 20 22 23
- 18 19 22 25
- 21 22 23 25
- 19 22 25 25
- 18 18 21 22
                  A. niger MTCC-282                                               A. Clavatus  MTCC-1323
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
Griseofulvin
Nystatin
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
IIIa IIIa IIIa
IIId IIIe
IIIe
IIIg
IIIi
IIId IIId IIIc IIId
IIIh IIIh IIId IIIe
IIIi IIIe IIIg
IIIf IIIh
IIIg IIIi
IIIh
IIIi
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”
           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Va-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO.3D : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 4-(4-METHOXYPHENYL)-6-METHYL-2-THIOXO-N-(PY-
RIDIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE.(Va-j).(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 10 13 16 20
- 12 14 18 21
- 10 13 14 17
- 12 14 15 21
- 10 12 15 18
- 12 13 14 17
- 11 14 16 17
- 12 13 15 20
- 11 12 15 18
10 12 13 15 17
 Compd
 No.
IIIk
IIIl
IIIm
IIIn
IIIo
IIIp
IIIq
IIIr
IIIs
IIIt
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 11 12 15 17
- 14 15 16 18
- 09 12 13 15
- 11 14 16 18
- 12 14 15 17
- 12 14 17 18
- 11 13 14 15
11 15 16 18 23
- 11 14 15 17
10 14 16 18 21
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
IIIt IIIl IIIk
IIIl
IIIn
IIIr
IIIr IIIl IIIl IIIl IIIl
IIIt IIIr IIIn IIIn IIIn
IIIt IIIo IIIp IIIp
IIIp IIIr IIIr
IIIr IIIt IIIt
IIIt
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Va-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 3E : COMPARATIVE ANTIMICROBIAL ACTIVITY OF4-(4-METHOXYPHENYL)-6-METHYL-2-THIOXO-N-(PY-
RIDIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE.(Va-j).(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 12 15 18 19
- 14 16 17 18
10 15 17 18 19
- 10 13 14 17
- 10 17 21 27
- 17 18 18 19
- 15 17 19 24
- 09 11 14 15
- 12 15 18 25
12 14 17 18 19
-
 Compd
 No.
IIIk
IIIl
IIIm
IIIn
IIIo
IIIp
IIIq
IIIr
IIIs
IIIt
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 10 11 12 16
- 09 11 14 15
- 12 14 17 19
- 11 13 15 17
- 13 15 18 21
- 09 12 14 15
- 14 15 16 19
- 07 10 11 12
- 11 15 18 21
- 12 13 15 18
                          E. Coli MTCC-443                                                        P. Aeruginosa  MTCC-424
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
IIIm IIIl       IIIl  IIIt IIIk IIIq IIIk IIIq
IIIt IIIm     IIImIIIq IIImIIIs IIImIIIs
IIIp      IIIo IIIoIIIt IIIoIIIt
IIIq      IIIp IIIp IIIp
IIIt
IIIo IIIm IIIm IIIm
IIIq IIIo IIIo IIIo
IIIq IIIq IIIq
IIIs IIIs IIIs
IIIt
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Va-j) with known choosen standard drugs
TABLE NO. 3F :COMPARATIVE ANTIMICROBIAL ACTIVITY OF 4-(4-METHOXYPHENYL)-6-METHYL-2-THIOXO-N-(PY-
RIDIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE.(Va-j).(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 18 19 21 22
- 18 20 22 22
- 21 22 23 25
- 19 21 22 25
- 18 20 22 25
- 18 19 22 25
- 21 22 23 25
- 19 22 25 25
- 18 18 21 22
- 22 22 24 24
 Compd
 No.
Ik
Il
Im
In
Io
Ip
Iq
Ir
Is
It
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 22 22 24 24
- 18 20 21 21
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
- 18 20 22 22
                  A. niger MTCC-282                                                A. Clavatatus MTCC-1323
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
Griseofulvin
Nystatin
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
IIIm IIIr
IIIn
IIIq
IIIt
IIIk IIIk IIIk IIIk
IIIm IIIm IIIm
IIIq IIIq IIIq
IIIt
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           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (VIa-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO.3G : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-N-(PYRI-
DIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE. (VIa-j). (Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 11 12 14 17
- 12 14 15 17
- 12 15 16 21
- 12 14 15 19
- 13 15 15 18
- 14 14 14 17
- 12 13 15 18
- 12 14 14 20
- 12 14 14 20
- 12 13 14 17
 Compd
 No.
IIIu
IIIv
IIIw
IIIx
IIIy
IIIz
IIIa’
IIIb’
IIIc’
IIId’
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
08 15 18 19 20
- 10 13 14 15
- 15 16 17 19
- 15 15 16 18
- 12 14 15 17
- 13 16 17 19
- 10 13 15 17
- 11 13 15 16
- 14 15 16 18
- 12 14 14 16
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
IIIy IIIw
IIIz IIIx
IIIb’
IIIc’
IIIu IIIuIIIc’ IIIu IIIu
IIIw IIIwIIId’ IIIw IIIw
IIIx IIIx IIIx IIIx
IIIz IIIy IIIz IIIz
IIIc’ IIIz IIIc’ IIIc’
12
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (VIa-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO.3H : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-N-(PYRI-
DIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE. (VIa-j).(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
08 13 15 17 19
- 09 12 14 15
- 10 15 17 18
- 11 15 16 17
- 11 12 15 18
- 13 15 16 17
- 13 17 19 22
07 12 16 20 21
- 17 18 18 19
11 14 17 18 23
 Compd
 No.
Iu
Iv
Iw
Ix
Iy
Iz
Ia’
Ib’
Ic’
Id’
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 11 12 14 17
- 08 11 14 16
- 11 12 13 15
- 10 11 14 15
08 13 15 18 20
- 10 11 12 16
- 13 15 18 20
- 12 15 17 19
09 11 12 14 17
10 12 15 19 22
                          E. Coli MTCC-443                                                        B. subtillis MTCC-441
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
IIIc’ IIIa’ IIIa’ IIIa’
IIIb’ IIIb’ IIIb’
IIIc’ IIIc’
IIId’
IIIy IIIy IIIy
IIIa’ IIIa’ IIIa’
IIIb’ IIId’ IIId’
IIId’
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (VIa-j) with known choosen standard drugs
TABLE NO.3I : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 2-IMINO-4-(4-METHOXYPHENYL)-6-METHYL-N-(PYRI-
DIN-2-YL)-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE. (VIa-j).(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
- 18 20 22 22
- 21 22 23 25
 Compd
 No.
IIIu
IIIv
IIIw
IIIx
IIIy
IIIz
IIIa’
IIIb’
IIIc’
IIId’
                R
C6H5
4-OCH3-C6H4
4-CH3-C6H4
4-F-C6H4
2-NO2-C6H4
3-NO2-C6H4
4-NO2-C6H4
4-Cl-C6H4
3-Cl-C6H4
2-Cl-C6H4
N.B.(-): No Activity  nN.
5 25 50 100 250
- 21 22 23 25
- 19 21 22 25
- 18 20 22 23
- 21 23 25 27
- 23 23 25 25
- 20 20 22 22
- 19 21 24 25
- 18 20 23 25
- 20 22 23 25
- 19 21 23 23
                  A. niger MTCC-282                                                 A. Clavatus MTCC-282
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
Griseofulvin
Nystatin
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
IIIv
IIIz
IIId’
IIIu IIIu IIIuIIIz IIIu
IIIx IIIx IIIvIIIa’ IIIv
IIIy IIIy IIIwIIIc’ IIIx
IIIc’ IIIxIIIc’ IIIy
IIIyIIId’ IIIa’
IIIb’
IIIc’
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PART - III
STUDIES ON 4-QUINOLONES
INTRODUCTION:
Benzene ring when fused with 2 and 3-positions of pyridine nucleus is known
as quinoline. Quinoline carboxylic acid in which quinoline ring is substituted by oxo
group either at 2 or 4 positions are well documented in literature as 2- quinolones (57)
and 4- quinolones (58) are well known due to their antimicrobial activities.
Structural formula of fluoroquinolones
Out of these two (57) and (58), 4 - quinolones constitute a large class of syn-
thetic antimicrobial agents that are highly effective in the treatment of many types of
infectious diseases, particularly those caused by bacteria. Quinolones are potent, broad
specturem antibacterial agents. The early congeners of the quinolone antibiotics which
is non-fluorinated at C-6 like nalidixic acid were limited to certain gram negative infec-
tions such as urinary tract infections. However, the modern generation of
fluoroquinolones containing C-6 fluoro substituent and a cyclic basic amine moiety at
C-7 surpass their predecessors in terms of spectrum of activity and potency. This has
allowed for their use against a variety of gram-negative as well as some gram-positive
pathogens. Quinolones are relatively easily prepared and administered via parenteral
and oral routes and are well tolerated.
The rapid rise in bacterial resistance to the traditional antibiotics such as  peni-
cillin and tetracyclines and their derivatives has encouraged a continuing search for
new classes of compound with novel modes of antibacterial activity.
The 4-quinolone antibiotics have emerged as an area of immense interest be-
cause of their broad spectrum of the in vivo activity and their in vivo chemothera-
peutic efficiency. Various structural modifications of this class of compounds have
provided the new agents such as ciprofloxacin214, ofloxacin215, lomefloxacin216 and
sparfloxacin217 which are considerably more potent and have a broader spectrum of
antibacterial activity.
N
O
R
R1
(57)
N
R
R1
O
(58)
R2 R2
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1928
1930
1942
1944
1945
1947
1949
1952
1955
1957
1961
Indicate milestiones in antibiotic
drug development.
Discovery  of  penicilin by alexa
nder fleming.
Discovery  of  the sulpha drugs.
Penicilline the first b-lactam drugs,
launches the antibiotic era.
Streptomycine, an aminoglyco
side is heralded as a cure for
tubnerculosis.
Tetracyclines are developed.
Chloramphenicol and the
aminogycosides neomycin and gen-
tamicin are introduced.
Macrolides such as erythromycin
enter the market.
The first glycopeptide vancomycin
is approved.
The rifamycin family of anti biotics
is discovered.
The dihydrofolate reductase inhibitor
drug trimethoprim is launched.
Indicate landmarks in the evolu-
tion of bacterial  resistance.
         Staphylococcus aureus
shows resistance against penicilin.
          Isolates of erythromycin resi
stant staphylococci reported  in jap
an ,england, france and the USA.
         Methicillin-resistant S. aureus
(MRSA) detected in the UK.
RACE -  AGAINST TIME : THE INTRODUCTION OF NEW ANTIBIOTIC CLAS-
SES  AND THE EMERGENCE OF RESISTANCE218
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1962
1967
1970
1982
1983
1986
1987
1990
1997
1998
2000
2003
The quinolone and the streptogra
mins are discovered.
Cefalexin, a first-generation cepha-
losporin, is launched.
The first fluoroquinolone, norfloxac
in, is approved for human use.
Linezolid, first in the novel oxazoli
dinone class of antibiotics, is approved.
A  new lipopeptide antibiotic, dapt
omycin, is approved.
          Penicillin-resistant Neisseria
gonorrhoeae and Streptococcus
pneumoniae reported.
        MRSA develops resistance to
cephalosporins.
         Penicillin-resistant  Entero-
coccus faecium is detected.
        Vancomycin-resistant entero-
cocci is detected.
        (Early 1990s) Multi-drug-resis-
tant Pseudomonas aeruginosa
seen in hospital-acquired infections.
        First vancomycin-resistant strain
of S. aureus is detected in japan.
           Isolation of linezolid-resistant
enterococci.
      (Early 2000s) Community -ac-
quired MRSA recognized as an
emerging pathogen.
        Linezolid-resistant  S. aureus
is reported.
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SYNTHETIC  METHODS OF 4-QUINOLONES
Oldfield William (1969) synthesized 1-phenyl-4-oxo-1,4-dihydroquinoline-3-
carboxylic acids219. Different synthetic methods for the synthesis of 4-quinolones
reported in the literature are as follows
(A) By the ethylation of 4-quinoline-3-carboxylic acid220.
(B) By the treatment of substituted acetophenones with ethylcarbonate and trie-
thyl orthoformate followed by the condensation with substituted phenyl
amines and further cyclization to afford 4-quinolone derivatives221.
(C) By the reduction of 4-(3-nitro phenyl)-pyridine followed by the condensation
with diethyl ethoxy methylene malonate and  on further cyclization  yielded
substituted 4-quinolone-3-carboxylic acids222.
(D) By the condensation of substituted anilines with dimethyl acetylene
dicarboxylate followed by thermal cyclization and hydrogenation223.
(E) By heating of 4-Fluoro-2-methyl-N-(2,2,2-trifluoroethyl)-aniline with polyphos
phoric acid at 110º C to afford 6-fluoro-4-oxo-1-(2,2,2-trifluoroethyl)-1,4-
dihydroquinoline-3-carboxylic acid224.
(F) 2,5-C2H5-(NH2)C6H3O(CH2)17CH3 on condensation with diethylethoxy
methylene malonates followed by the cyclization  with  POCl3 to afford
substituted quinolone-3-carboxylic acids225.
(G) By the reaction of diethylethoxy methylene malonates with secondary
aromatic amine in the presence of polyphosphoric acid to yield 4-quinolone
3-carboxylic acids226.
(H) By heating N-(b-dicarboxy ethyl ethylene)-substituted aniline on heat
ing at  250 to 2550C affords 4-quinolone-3-carboxylic acid 225.
(I). 2,4-dichloro-5-fluoro benzoyl chloride on condensation with malonic ester
followed by decarboxylation and condensation with ethyl formate which on
treatment with cyclo propyl amine followed by cyclization and  reaction with
piperazine yielded ciprofloxacine227.
(J) By the reaction of substituted acid chlorides with diethyl malonate in the
presence of magnesium followed by cyclization229.
(k) N-Hydroxy succinimide ester of anthranillic acid upon reaction with
anions of ß-keto esters to give 4-oxo-3-quinoline carboxylic acid
derivatives230.
(L) By the condensation of ß-keto ester and p-anisidine in polypho-
sphoric acid yields 2-(phenoxy difluoromethyl-6-methoxy-1H-
quinoline-4-one231.
(M) 3-Amino-2-phenyl-4(1H)-quinolones are obtained from anthranilami-
des232.
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N
O O
OH
N
NH
CH3
CH3
F
F
NH2
Sparfloxacin
N
O O
OH
N
N O
F
CH3 CH3
S(-)Levofloxacin
N
O O
OH
O
F
CH3
N
H
H
H N
O O
OH
F
N
H
H
NH2
F
F
TrovafloxacinMoxifloxacin
(1) Nadifloxacin(anti bacterial) (2) Ciprofloxacin
(3) Gatifloxacin(anti bacterial) (4) Satifloxacin
(5) Ofloxacin(anti bacterial) (6) Garenoxacin
(7) Gemifloxacin (8) Nalidixic acid(Urinary tract infe.)
(9) Cinoxacin (10) Norfloxacin(Gyrase inhibitor)
(11) Enoxacin(Gyrase inhibitor) (12)Lomefloxacin
(13) Temafloxacin (14) Pefloxacin(Gyrase inhibitor)
(15) Enrofloxacin (16) Flumequine
(17)Tosufloxacin (18) Pipemidic acid (Urinary tract infe.)
(19) Amifloxacin (20) Oxalinic acid (Gyrase inhibitor)
(21) Miloxacin (22) Difloxacin
(23) Fleroxacin (24) Alatrofloxacin mesilate
(25)Grepafloxacin (26) Rufloxacin(anti bacterial)
(27) Rosoxacin(anti biotic) (28) Piromidic acid (chemotherapeutic
(29) Flose quinon(vasodilator) (30) Nedocronil(Anti allergic)
(N) By the condensation of substituted acetophenones and cyclopropyl amine
and dimethyl sulphate followed by the cyclization affords 4-quinolone-3-
carboxylates233.
Some of the important 4-quinolones which are used in clinical trial as antibiot-
ics can be summarized as under with several structures234.
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STRUCTURE- ACTIVITY RELATIONSHIP
4-Quinolone carboxylic acids constitute a class of extremely potent and orally
active broad spectrum antibacterial agents235-238. These compounds have been
shown to affect the bacterial growth by inhibiting the DNA gyrase, a key enzyme in
bacterial DNA replication239-240.
The substituiton of a piperazinyl ring at position 7 has rendered  the molecule
active against Pseudomonas and the presence of a fluorine atom at position 6 ex-
tends the activity of the molecule to some but not all gram-positive
bacteria242.Streptococcus can be resistant241. Additions of alkyl chains to the nitro-
gen at position 1, increase the activity of the compounds. The substitution of hydrogen
atoms by fluorines at position 8 of the ring and on the methyl of the alkyl chain dimin-
ishes the rate of degradation and decreases the rate of elimination.
It was widely believed  that 3-carboxylic acid and 4- carbonyl were necessary
for the antimicrobial activity of the compounds. However,Chu et.al.243 a showed that
the transformation of existing molecules in 2,3,4,9-tetrahydroisothiazolo[5,4-b] quino-
line-3,4-diones produces a significant increase in their biological activity244.
 Overview of SAR of Fluoroquinolones anti bacterial drugs,245,246.
Y- N
O O
OH
R3
R5
R4
R1
R2
R6
Moderate Influence on 
potency Cardiotoxicity Essential for gyrase binding
and bacterial memdrane 
transport
Infuences potency 
spectrum, Pk
Controls Pk (oral absorbance) 
Phototoxicity
Infuences potency and 
Pk::. antigenicity.
Controls gyrase and anti 
bacterial potency
(2)
Limited changes 
influences
1. Subtituent at N-1 position: A compilation of active N-1 quinolone substituents
is shown below with an emphasis on overall in vitro potency.
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The simple replacement of C-2 hydrogen has generally to be disadvan tage
ous,e.g. C-2 methyl or hydroxyl groups. However,some derivatives containing a suit-
able C-1,C-2 ring have been shown to possess notable activity.e.g. Prulifloxacin.
N
O
F
O
OH
S
CH3
N
N
OO
O
CH3 (60)
3. Without doubt, the C-3 carboxylic acid moiety is most commonly encountered.
Other acidic groups such as sulphonic acid, phosponic acid, tetrazole as well as
derivatisation as an ester results in a loss of antibacterial activity.
4. The C-4-oxo group of the quinolone nucleus appears to be essential for anti-
bacterial activity. Replacement with 4-thioxo or sulphonyl group leads to a loss of ac-
tivity.
5. The incorporation of an amino group at the C-5 position has proven benefical
in terms of antibacterial activity. The order of activity at R3: NH2, CH3>F, H>OH, OR,
SH, SR.
6. The incorporation of a fluorine atom at the C-6 position of the quinolone is
monumental, the order of activity at R4: F.>Cl,  Br, CH3 >CN.
7. The introduction of a piperazine moiety at C-7 was a land mark devlopment.
Other aminopyrrolidines also are compatible for activity..
R7: NNH
R
NN, > >N
NH2
N
(61)
8. A hydrogen atom at the C-8 or a nitrogen atom (a napthyridone) is the most
common. In general, a C-8 fluoro substitutent offers good potency against gram-nega-
> -C2H5,
F
F
,-CH2CH2F,  -CH=CH2 > CH3 CH3
CH3
Enhanced gram-positive
 potency
-NHCH3, -OCH3>
Enhanced potency
against anarobes
(59)
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tive pathogens, while a C-8 methoxy moiety is active against gram-positive bacteria.
The order of activity at R6; F, Cl, OCH3, >H, CF3> methyl, vinyl, propagyl.
9. A halogen (F or Cl) at the 8-position improves oral absorption.
10. The joining of N-1 group to the C-8 position with oxazine ring leads to active
ofloxacine.
MEDICENAL INTEREST :-
The research on 4-quinolones system is of current interest due to their
valuable activities as Antibiotic, DNA gyrase inhibitors, Anti bacterial  etc.
Besides the currently established drugs like Norfloxacin ,Ciprofloxacin, many 4-
quinolone derivatives have been synthesized world wide and have led to nu-
merous second generation commercial products such as Ofloxacin, Gatifloxacin,
Pipemidic acid. By the literature survey, it was found that 4-quinolones possess
wide variety of biodynamic activity. which can be put forward as under.
[A]  Analgesic activity247-250
[B]  Antiallergic activity251-455
[C]  Antiasthmatic activity256-257
[D]  Antibacterial activity258-276
[E]  Anticancer activity277
[F]  Anticoccidial activity249,262,278-279.
[G]  Antiinflammatory activity280-281
[H]  Antinaphylatetic activity282
[I]    Antipyretic activity247
[J]   Antirheumatism activity247
[K]   Antispasmolytic activity283
[L]   Antitumor activity284-286
[M]  Antiulcer activity287
[N]  Bacteriostatic activity289
[O]  CNS depressant activity248,290
[P]  Diuretic activity290-291
[Q]  Hypnotic activity292
[R]  Hypotensive activity248
[S]  Pressure lowering activity293
[T]  Tranquilizer activity291
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[U]  Tuberculosis activity293-294
[V]   Antimalarials295
[W]  Topoisomerase inhibitors296-297
[X]  CB2 cannabinoid receptors agonists298
Recently, K.S.Aithal et.al.299 have reported uses of norfloxacin for bone joint
urinary tract,respiratory tract infection and also for maningitis. Antimicrobial and anti-
fungal activity of 4-quinolones have been reported by M.B.Deshmukh et.al.300-301
Anti allergic activity studies of quinolones (62) and imidazoquinolinones(63)
have been reported by N. P. Peet et al.254, which established the SAR conclusion that
amine and ester functions at the position 8 and 3 respectively were necessary for the
significant  anti allergic activity.
N
O
N
R1
O
O
R3
R2
N
O
R5
R4
R1
R2 R3
(62) (63)
H. Takayama et.al302 have isolated new alkaloid (64) from leaves of Gardneria
nutans having a novel 4-quinolone ring skeleton.
N
H
O
N
H
O
OH
CH3
HOH
(64)
The alkaloid was obtained from crude basic fraction of the leaves of gardne -
ria nutans in its unique structure having a 4-quinolone moiety.
R. Singh et al303  have reported the synthesis and antibacterial activity of 7-
hydrazinoquinolones (65).
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X N
O
NH
O
OH
N
Y
F
R1
R
(65)
Gaurav gruver et. al.245  have designed  the synthesis of  1,3,4-oxadiazoles
and 1,3,4-oxadiazole-2-thione derivatives of nalidixic acid (66)  and  (67) as potent
anti bacterial and fungicidal agents.
     
(66)
R1= p-Cl, p-OH, o,m-di nitro, phenyl
N N
O
CH3
N
O
N
CH3
R1
N N
O
CH3
N
O
N
H
CH3
S
(67)
Chengxin  Zhi  et. al.297 have reported the synthesis of  a novel hybrid antibac-
terial agents (68) of  6-(3-ethyl-4-methylanilino)uracils (EMAU) and fluoroquinolones
moiety (FQ) as potent DNA  polymerase- topoisomerase inhibitors and showed that
the resulting AU-FQ hybrid compounds were significantly more potent than the parent
‘EMAU’ compounds.
N
N
H
O
O
NH
CH3
CH3
(CH2)4
N
O O
OH
N
N
CH3
F
F
(68)
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Recently, synthesis and antimicrobial activity studies of novel amide deriva-
tives of 4-quinolones (69) and (70) have been reported by H.I.Chauhan and et.al.20.
N
O
Cl
F
O
NH
N
O
R1
F
O
NH
R R
(69) (70)
R=H,-OCH3,O-Cl,m-CH3,o-NO2----etc 
R1=N-methyl piperazine,N-ethyl, 
morpholine.etc
A. Carta et.al.304have studied the antitubercular activity of some new
(1,2,3)Triazolo(4,5-h)quinolones (71) aganist the multidrug resistant Mycobacterium
tuberculosis strains (H37Rv).
N
O O
R1
OR
NN
NCH3
(71)
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Recently, antimycobacterial and toxicological evaluation of novel ofloxacin de-
rivatives (72) have been reported by M.Dinakaran et.al305.
N
O O
OH
R1
O
CH3
R
F
(72)
In our further studies and in order to evaluate the biodynamic activities, synthe-
sis of 4-quinolone derivatives were undertaken,  which can be summarised in the fol-
lowing sections.
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SECTION - IV: PREPARATION AND BIOLOGICAL EVALUATION OF
ETHYL- 6-CHLORO / FLUORO /METHYL / METHOXY/
NITRO-7-CHLORO/METHYL-1-N-PROPYL-1,4-DIHY-
DROQUINOLINE-4-ONE-3-CARBOXYLATES.
SECTION - V: PREPARATION AND BIOLOGICAL EVALUATION OF 6-
CHLORO / FLUORO / METHYL / METHOXY/NITRO-7-
CHLORO/METHYL-4-OXO-1-PROPYL-1,4-DIHYDRO-
QUINOLINE-3-CARBOXYLIC ACIDS.
SECTION - VI: PREPARATION AND BIOLOGICAL EVALUATION OF 6-
FLUORO - 7 - N-ETYHL PIPERAZINYL / N,N-DICHLO-
ROETYL /  MORPHOLINYL /  N-PHENYL PIPERAZINYL
/ N- METHYL PIPERAZINYL / PIPERIZINYL /  N,N- DI-
ETHYL/  2-PYRIDYL AMINO  / 2-PYRIMIDYL AMINO -
4-OXO-1-N-PROPYL-1,4-DIHYDROQUINOLINE-3-CAR-
BOXYLIC ACIDS.
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SECTION - IV
PREPARATION AND BIOLOGICAL EVALUATION OF ETHYL- 6-CHLORO/
FLUORO/METHYL/METHOXY/NITRO-7-CHLORO/METHYL-1-N-PROPYL-
1,4-DIHYDROQUINOLINE-4-ONE-3-CARBOXYLATES (IVa-j).
Keeping in view of various biodynamic activities34-85 of 4-quinolones
and in order to have highly potent therapeutic agents, the synthesis of Ethyl-
-6-chloro/fluoro/methyl/methoxy/nitro-7-chloro/methyl-1-N-propyl-1,4-
di-hydroquinoline-4-one-3-carboxylates (IVa-j) have been prepared by the
condensation of different ethyl-6-chloro/flouro/methyl/methoxy-7-chloro/
methyl-1,4-dihydroquinoline-4-one-3-carboxylates and 1-bromo pro-
pane in the presence of basic condition.
The constitution of the products (IVa-j) have been delineated by elemen-
tal analysis, IR, PMR and Mass spectral data.
The products (IVa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 ,S. aureus MTCC-96
and B. subtillis MTCC-441(Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations.i.e.:
0(control),5, 25, 50, 100, 250 (μg/ml)  for their MIC (Minimum Inhibitory Con-
centration) values. The biological activities of the synthesized compounds were
compared with standard drugs viz. ,Amoxicil l in,Chloramphenicol,
Sparfloxacin,Levofloxacin(antibacterial), Griseofluvin, Fluconazole (an-
tifungal).
 ( IVa-j )
R=Chloro/fluoro/Methyl/Methoxy/Nitro
R
N
O O
O CH3
CH3
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REACTION SCHEME
N
H
O O
O CH3
R
Anhyd. K2CO3
N
O O
O CH3
CH3
R
CH3
Br
(IVa-j)
R = Chloro / Fluoro / Methyl / Methoxy / Nitro
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF ETHYL-6-CHLORO/
FLUORO/METHYL/METHOXY/NITRO-7CHLORO/METHYL-1-N-PROPYL-
1,4-DIHYDROQUINOLINE-4-ONE-3-CARBOXYLATES (IVa-j).
(A)  Preparat ion of  Ethyl -7-chloro-6- f luoro-1-N-propyl -1 ,4-
dihydroquinoline-4-one-3-carboxylate(IVd ).
A mixture of Ethyl-7-chloro-6-fluoro-1,4-dihydroquinoline-4-one-3-
carboxylate(lVd).(2.69 gm, 0.01 M) and potassium carbonate(2.76 gm,
0.02M), in dimethyl sulphoxide (20 ml) was heated and stirred at 110 to120
OC for 1 hrs. and then allowed to cool up to the temp 60 to70OC. To this reac-
tion mixture, the solution of 1-bromo propane (1.22 gm, 0.01M) in dimethyl
sulphoxide (6 ml) was added dropwise and the temperature was maintained
95 to100OC for  8 hrs.The resulting mixture was poured on to crushed ice,
filtered, washed with water and dried. The product was recrystallized from etha-
nol. Yield : 47%, M.P. : 103 OC, Rf : (1) 0.61 (2) 0.62 (Required : C,62.04%;
H,6.30 %; N,4.49 %  for C19H23NO3ClF Found : C, 62.01 %; H, 6.27 %; N,
4.46%).
TLC  solvent system   Rf1  : Ethyl acetate : hexane =  5.0 : 5.0
     Rf2    : Methanol : Chloroform =  0.5 : 9.5
Similarly, other compounds (IVa-j)  were synthesized. The physical
data are recorded in Table No. 4.
(B)  Antimicrobial activity of Ethyl-6-chloro/fluoro/methyl/methoxy/nit-
ro-7-chloro/methyl -1-N-propyl-1,4-dihydro quinoline-4-one-3-carboxy-
lates (IVa-j ).
Antimicrobial activity testing was carried out as described in Part-1,
Section-I, page No.30-31. The MIC values of test solution are recorded in Table
No. 4A, 4B and 4C.
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IR  SPECTRAL STUDY OF ETHYL-6-CHLORO-1-N-PROPYL-1,4-
DIHYDRO QUINOLINE-4-ONE-3-CARBOXYLATE (IVc).
N
O O
O CH3
CH3
Cl
(IVc)
Alkane
(methyl &
methylene)
Aromatic and
ring skeletal
vibration
Amine
Ketone
(4-quinolone)
(ester)
Halogen
Subtitution
Para(-4-)
substituted
Frequency in cm-1
Observed Reported
Reference
2975 - 2850
2900 - 2800
1470 - 1435
1385 - 1300
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   800
1340 - 1250
3400 - 3000
1650 - 1550
1710 - 1640
1740 - 1650
1400 - 1080
800 - 850
Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
N-H (str., b)
N-H (def., s,m)
C=O (str., s)
C=O (str., s)
C-F (str., b)
C-H (def., v,s)
2906.8
2852.8
1452.4
1367.5
3066.9
1502.6
1124.2
802.4
1367.5
3203-
3003
1618.3
1710.9
1732.1
1390.7-
1161.1
837.1
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
310
310
310
310
311
311
309
309
311
312
312
312
312
311
312
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NMR  SPECTRAL STUDY OF ETHYL-6-CHLORO-1-N-PROPYL-1,4-
DIHYDRO QUINOLINE-4-ONE-3-CARBOXYLATE (IVC).
Signal
No.
Signal Position
(δ ppm) Multiplicity
Inference
1
2
3
4
5
6
7
8
9
triplet
quartet
singlet
doublet
doublet
singlet
triplet
singlet
singlet
- CH3(a)
- CH2(b)
- Ar-H(c)
- Ar-H(d)
- Ar-H(e)
-N-CH(f)
- CH2(g)
- CH2(h)
- CH2(i)
3H
2H
1H
1H
1H
1H
2H
2H
3H
1.3159-1.3188
4.1093-4.1119
7.3922
7.5130-7.5558
8.1414-8.2124
8.4948
2.9172-2.9178
1.7112-1.7121
0.9538-0.9558
Relative No.
of Protons
(IVc)
N
O O
O CH3
CH3
Cl
a
bc
d
e
f
g h
i
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m/z = 131 (m+1)
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           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ia-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO.4A : COMPARATIVE ANTIMICROBIAL ACTIVITY OF ETHYL-6-CHLORO/FLUORO/METHYL/METHOXY/
NITRO-7-CHLORO/METHYL-1-N-PROPYL-1,4-DIHYDROQUINOLINE-4-ONE-3-CARBOXYLATES(IVa-j).(Different
Inhibition Concentration in μg/ml).
5 25 50 100 250
- 12 15 16 21
- 12 14 15 19
- 10 13 15 18
- 10 12 14 17
- 11 13 15 18
- 12 14 16 20
- 12 15 18 20
- 12 13 14 17
- 12 15 18 21
- 11 14 15 18
 Compd
 No.
IVa
IVb
IVc
IVd
IVe
IVf
IVg
IVh
IVi
IVj
                R
6-F
7-Cl
6-Cl
7-Cl-6-F
6,7-(Cl)2
6-NO2
6-OCH3
6-CH3
7,8-(CH3)2
-
N.B.(-): No Activity  nN.
5 25 50 100 250
- 11 15 16 18
- 12 14 15 16
- 08 12 13 14
- 12 14 15 16
- 09 11 12 14
- 11 12 15 17
09 14 15 16 18
- 11 14 15 16
- 11 15 16 17
- 13 16 17 19
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
IVg IVa
IVi IVb
IVf
IVg
IVi
IVg     IVa IVh IVa IVa
IVj      IVb IVi IVg IVg
          IVd IVj IVi IVj
          IVg IVj
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ia-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 4B : COMPARATIVE ANTIMICROBIAL ACTIVITY OF ETHYL-6-CHLORO/FLUORO/METHYL/METHOXY/
NITRO-7-CHLORO/METHYL-1-N-PROPYL-1,4-DIHYDROQUINOLINE-4-ONE-3-CARBOXYLATES(IVa-j).(Different
Inhibition Concentration in μg/ml).
5 25 50 100 250
- 12 15 17 18
- 11 13 16 17
10 12 13 15 18
- 13 15 16 17
- 14 15 16 17
- 10 12 15 17
- 17 18 20 21
- 10 12 15 17
- 11 13 14 15
- 10 13 15 17
 Compd
 No.
IVa
IVb
IVc
IVd
IVe
IVf
IVg
IVh
IVi
IVj
                R
6-F
7-Cl
6-Cl
7-Cl-6-F
6,7-(Cl)2
6-NO2
6-OCH3
6-CH3
7,8-(CH3)2
-
N.B.(-): No Activity  nN.
5 25 50 100 250
- 10 11 13 17
- 09 12 13 15
- 11 13 16 19
- 08 10 11 12
- 10 13 15 17
- 08 10 11 13
09 11 13 18 19
- 08 13 15 17
- 10 12 14 15
- 10 14 15 16
                          E. Coli MTCC-443                                                        P. Aeruginosa MTCC-1688
 Amoxiciline
 Chloramphenicol
 Sparfloxacin
 Levofloxacin
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
IVgIVg IVg IVg IVg
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ia-j) with known choosen standard drugs
TABLE NO. 4C : COMPARATIVE ANTIMICROBIAL ACTIVITY OF ETHYL-6-CHLORO/FLUORO/METHYL/METHOXY/
NITRO-7-CHLORO/METHYL-1-N-PROPYL-1,4-DIHYDROQUINOLINE-4-ONE-3-CARBOXYLATES(IVa-j).(Different
Inhibition Concentration in μg/ml).
5 25 50 100 250
- 18 20 22 23
- 18 19 22 25
- 21 22 23 25
- 19 22 25 25
- 18 18 21 22
- 22 22 24 24
- 18 20 21 22
- 21 21 23 24
- 22 25 25 25
- 18 20 22 23
 Compd
 No.
IVa
IVb
IVc
IVd
IVe
IVf
IVg
IVh
IVi
IVj
                R
6-F
7-Cl
6-Cl
7-Cl-6-F
6,7-(Cl)2
6-NO2
6-OCH3
6-CH3
7,8-(CH3)2
-
N.B.(-): No Activity  nN.
5 25 50 100 250
- 18 19 21 22
- 18 20 22 22
- 21 22 23 25
- 19 21 22 25
- 21 23 25 27
- 23 23 25 25
- 20 20 22 22
- 19 21 24 25
- 18 18 19 22
- 18 19 21 22
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
                  A. niger MTCC-282                                               A. clavatus MTCC-1323
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
Griseofulvin
Nystatin
IVc IVi IVi
IVd
IVf
IVh
IVi
IVc IVc IVb IVc
IVe IVe IVc IVd
IVf IVf IVd IVe
IVe IVf
IVf IVh
IVg
IVh
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SECTION - V
PREPARATION AND BIOLOGICAL EVALUATION OF 6-CHLORO/
FLUORO/METHYL/METHOXY/NITRO-7-CHLORO/METHYL-4-OXO-1-PRO-
PYL-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACIDS (Va-j) .
Keeping in view of various biodynamic activities34-85 of 4-quinolones
and in order to have highly potent therapeutic agents, the synthesis of 6-chloro/
fluoro/methyl/methoxy/nitro-7-chloro/methyl-4-oxo-1-propyl-1,4-dihy-
droquinoline-3-carboxylic acids (Va-j) have been prepared by the hydroly-
sis of different ethyl-6-chloro/fluoro/methyl/methoxy/nitro-7-chloro/me-
thyl-1,4-dihydroquinoline-4-one-3-carboxylates and 1-bromo propane in
the presence of basic condition.
The constitution of the products (Va-j) have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (Va-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 ,S. aureus MTCC-96
and B. subtillis MTCC-441(Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations.i.e.:
0(control),5, 25, 50, 100, 250 (μg/ml)  for their MIC (Minimum Inhibitory Con-
centration) values. The biological activities of the synthesized compounds were
compared with standard drugs viz. ,Amoxicil l in,Chloramphenicol,
Sparfloxacin,Levofloxacin(antibacterial), Griseofluvin, Fluconazole (an-
tifungal).
R
N
O O
OH
CH3
 ( Va-j )
R=Chloro/fluoro/Methyl/Methoxy/Nitro
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REACTION SCHEME
20 %  aq. NaOH soln.
N
O O
OH
CH3
R
N
O O
O CH3
CH3
R
Δ
(Va-j)
R = Chloro / Fluoro / Methyl / Methoxy / Nitro
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF  6-CHLORO/
FLOURO/METHYL/METHOXY-7-CHLORO/METHYL-4-OXO-1-N-PROPYL-
1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACIDS (Va-j) .
(A) Preparation 6-chloro-1-N-propyl-1,4-dihydro quinoline-4-one-3-
carbo-xylic acids(Vc ).
A mixture of 6-chloro-4-oxo-1-propyl-1,4-dihydroquinoline-3-car-
boxylates(2.69 gm, 0.01 M) and sodium hydroxide (20 %) was heated at
110 to 120 OC for 5 hrs. and then allowed to cool up to the temp 60 to70OC. To
this reaction mixture, the solution of dilute HCl  was added dropwise .The
resulting mixture was poured on to crushed ice, filtered, washed with water
and dried. The product was recrystallized from ethanol. Yield : 46%, M.P. :
156 OC, Rf : (1) 0.59 (2) 0.46 (Required : C,62.04%; H,6.30 %; N,5.27 %  for
C19H23NO3ClF Found : C, 62.01 %; H, 6.27 %; N, 5.23%).
TLC  solvent system  Rf1  : Ethyl acetate : hexane =  5.0 : 5.0,
     Rf2 : Methanol : Chloroform =  0.5 : 9.5.
Similarly, other compounds (Va-j)  were synthesized. The physical data
are recorded in Table No. 5.
(B)  Antimicrobial activity of 6-chloro/fluoro/methyl/methoxy/nitro-7-
chloro / methyl-1-N-propyl-1,4-dihydro quinoline-4-one-3-carboxylic
acids (Va-j ).
Antimicrobial activity testing was carried out as described in Part-1,
Section-I, page No.30-31. The MIC values of test solution are recorded in Table
No. 5A,5B,5C.
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Alkane
(methyl &
methylene)
Aromatic and
ring skeletal
vibration
Amine
Ketone
(4-quinolone)
Halogen
Subtitution
Para(-4-)
substituted
Frequency in cm-1
Observed Reported
Reference
2975 - 2850
2900 - 2800
1470 - 1435
1385 - 1300
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   800
1340 - 1250
3400 - 3000
1650 - 1550
3300 - 3800
1710 - 1640
1800 - 1750
1400 - 1080
800 - 850
Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
N-H (str., b)
N-H (def., s,m)
O-H (str., b)
C=O (str., s)
C=O (str., s) acid
C-F (str., b)
C-H (def., v,s)
IR SPECTRAL STUDY OF 6-CHLORO-1-N-PROPYL-1,4-DIHYDRO-
QUIN-OLINE-4-ONE-3-CARBOXYLIC ACID (Vc).
2903.8
2858.8
1452.4
1372.4
3058.8
1502.6
1124.2
811.1
1367.5
3203-
3003
1620.3
3685.1
1710.9
1800.1
1390.7-
1161.1
837.1
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
310
311
311
310
310
310
310
312
312
309
310
311
310
311
310
310
(Vc)
N
O O
O H
C H 3
C l
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NMR  SPECTRAL STUDY OF 6-CHLORO-1-N-PROPYL-1,4-DIHYDRO-
QUINO-LINE-4-ONE-3-CARBOXYLIC ACID (Vc).
Signal
No.
Signal Position
(δ ppm) Multiplicity
Inference
1
2
3
4
5
6
7
8
triplet
multiplet
triplet
singlet
doublet
singlet
singlet
singlet
- CH3(g)
- CH2(h)
- CH2(f)
- Ar-H(e)
- Ar-H(d)
- Ar-H(c)
-CH(b)
-O-H(a)
3H
2H
2H
1H
1H
1H
1H
1H
1.0449-1.0753
1.9648-2.1896
3.7262-3.7278
7.8664
7.8816-7.8827
8.6864
8.8924
11.0324
Relative No.
of Protons
N
O O
OH
CH3
Cl
a
c
d
e
b
f
g
h
(Vc)
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           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ik-t) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 5A : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 6-CHLORO/FLOURO/METHYL/METHOXY-7-CHLORO/
METHYL-4-OXO-1-PROPYL-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACIDS (Va-j)(Different Inhibition Concentra-
tion in μg/ml).
5 25 50 100 250
- 12 14 14 21
- 12 14 15 19
- 12 15 16 21
- 12 14 15 19
- 10 13 15 18
- 09 12 14 17
- 12 13 15 18
- 12 14 16 20
- 11 13 15 20
- 10 13 15 17
 Compd
 No.
Va
Vb
Vc
Vd
Ve
Vf
Vg
Vh
Vi
Vj
                R
6-F
7-Cl
6-Cl
7-Cl-6-F
6,7-(Cl)2
6-NO2
6-OCH3
6-CH3
7,8-(CH3)2
-
N.B.(-): No Activity  nN.
5 25 50 100 250
- 10 13 15 17
- 11 13 15 16
- 14 15 16 18
- 12 14 15 16
- 11 13 14 16
- 12 14 15 16
- 08 11 12 12
- 11 12 15 17
- 14 15 16 18
- 11 13 15 16
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
Vc
Vi
Vc
Vd
Vf
Vi
Vc
Vi
Vc
Vi
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (Ik-t) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 5B : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 6-CHLORO/FLOURO/METHYL/METHOXY-7-
CHLORO/METHYL-4-OXO-1-PROPYL-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACIDS (Va-j)(Different Inhibition
Concentration in μg/ml).
5 25 50 100 250
- 12 15 18 19
- 08 13 15 17
- 07 11 14 15
- 11 14 15 18
- 12 13 15 17
- 17 18 18 19
- 11 13 15 17
- 10 11 14 15
- 15 15 17 18
10 15 17 18 19
                R
6-F
7-Cl
6-Cl
7-Cl-6-F
6,7-(Cl)2
6-NO2
6-OCH3
6-CH3
7,8-(CH3)2
-
N.B.(-): No Activity  nN.
5 25 50 100 250
- 10 11 12 16
- 09 12 13 15
- 10 13 14 16
- 06 10 11 13
- 10 13 15 18
- 11 11 11 13
- 11 12 14 15
- 10 13 15 17
- 12 12 14 15
- 11 11 11 13
                          E. Coli MTCC-443                                                        P. Aeruginosa MTCC-1688
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
 Compd
 No.
Va
Vb
Vc
Vd
Ve
Vf
Vg
Vh
Vi
Vj
Vf Vf
Vi Vj
Vj
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIa-j) with known choosen standard drugs
TABLE NO. 5C : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 6-CHLORO/FLOURO/METHYL/METHOXY-7-
CHLORO /METHYL-4-OXO-1-PROPYL-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACIDS (Va-j)(Different Inhibition
Concentration in μg/ml).
5 25 50 100 250
- 18 19 22 25
- 21 22 23 25
- 19 22 25 25
- 18 18 21 22
- 22 22 24 24
- 18 20 21 22
- 21 21 23 24
- 18 18 19 22
- 18 19 21 22
- 18 20 22 22
 Compd
 No.
Va
Vb
Vc
Vd
Ve
Vf
Vg
Vh
Vi
Vj
                R
6-F
7-Cl
6-Cl
7-Cl-6-F
6,7-(Cl)2
6-NO2
6-OCH3
6-CH3
7,8-(CH3)2
-
N.B.(-): No Activity  nN.
5 25 50 100 250
- 18 20 22 22
- 21 22 23 25
- 19 21 22 25
- 21 23 25 27
- 23 23 25 25
- 20 20 22 22
- 19 21 24 25
- 18 20 23 25
- 20 22 23 25
- 19 21 23 25
                  A. niger MTCC-282                                               A. clavatus MTCC-227
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
Griseofulvin
Nystatin
Vb Vc
Vc
Ve
Vg
Vb Vb Va Vf VbVh
Vd Vd VbVg VcVi
Ve Ve VcVh VdVj
Vf VdVi Vi
Ve Ve Vj Vg
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SECTION - VI
PREPARATION AND BIOLOGICAL EVALUATION OF 6-FLUORO-7- N-
ETYHL PIPERAZINYL / N,N-DICHLOROETYL /  MORPHOLINYL /  N-PHENYL
PIPERAZINYL / N- METHYL PIPERAZINYL / PIPERIZINYL /  N,N- DIETHYL
AMINO  /  2-PYRIDYL AMINO  / 2-PYRIMIDYL AMINO -4-OXO-1-N-PROPYL-
1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACIDS (VIa-j) .
Keeping in view of various biodynamic activities34-85 of 4-quinolones
and in order to have highly potent therapeutic agents, the synthesis of 6-Fluoro-
7-N-ethyl piperazinyl, / N,N-dichloroethyl /  morpholinyl /  N-phenyl piperazinyl
/ N-methyl piperazinyl /piperazinyl /  N,N-diethyl amino /  2-pyridyl amino  / 2-
pyrimidyl amino -1-N-propyl-1,4-dihydro quinoline-4-one-3-carboxylic
acids(VIa-j) have been prepared by the cyclocondensation of different -1,4-
dihydroquinoline-4-one-3-carboxylic acids and N-ethyl piperazine,  N,N-
dichloroethyl /  morpholine /  N-phenyl piperazine / N-methyl piperazine /
piparazine /  N,N-diethyl amine  /  2-amino pyridine / 2-amino pyrimidine in the
presence of basic condition.
The constitution of the products (VIa-j) have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (VIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 ,S. aureus MTCC-96
and B. subtillis MTCC-441(Gram positive) and E. coli MTCC-443 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations.i.e.:
0(control),5, 25, 50, 100, 250 (μg/ml)  for their MIC (Minimum Inhibitory Con-
centration) values. The biological activities of the synthesized compounds were
compared with standard drugs viz. ,Amoxicil l in,Chloramphenicol,
Sparfloxacin,Levofloxacin(antibacterial), Griseofluvin, Fluconazole (an-
tifungal).
(VIa-j)
   R=Substituted  phenyl
N
O O
OH
CH3
R
F
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REACTION SCHEME
Pyridine
 R= N-ethyl piparazinyl, / N,N-dichloroethyl /  
morpholinyl /  N-phenyl piparazinyl / N-methyl 
piparazinyl / piparazinyl /  N,N-diethyl amino  /  
2-pyridyl  amino / 2-pyrimidyl amino 
N
O O
OH
CH3
R
F
(IVa-j)  
N
O O
OH
CH3
F
Cl
(Va-j)
Δ/ 
RNH / R2NH
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 6-FLUORO-7- N-
ETYHL PIPERAZINYL / N,N-DICHLOROETYL /  MORPHOLINYL /  N-PHENYL
PIPERAZINYL / N- METHYL PIPERAZINYL / PIPERIZINYL /  N,N- DIETHYL AMINO
/  2-PYRIDYL AMINO / 2-PYRIMIDYL AMINO -4-OXO-1-N-PROPYL-1,4-
DIHYDROQUINOLINE-3-CARBOXYLIC ACIDS (VIa-j) .
PREPARATION OF 6-FLUORO-7- N-PHENYL PIPERIZINYL-4-OXO-1-PRO-
PYL-1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID (VIc).
A mixture of ethyl 6-chloro-4-oxo-1-N-propyl-1,4-dihydroquinoline-
3-carboxylic acid (2.69 gm, 0.01 M) and N-phenyl piparazine was heated
at 110 to 120 OC for 5 hrs. and then allowed to cool up to the temp 60 to70OC.
To this reaction mixture, the solution of dilute HCl  was added dropwise .The
resulting mixture was poured on to crushed ice, filtered, washed with water
and dried. The product was recrystallized from ethanol. Yield : 61%, M.P. :
302 OC, Rf : (1) 0.59 (2) 0.55 (Required : C,62.04%; H,6.30 %; N,10.26 %
for C19H23NO3ClF Found : C, 62.01 %; H, 6.27 %; N, 10.25%).
TLC  solvent system  Rf1  : Ethyl acetate : hexane =  5.0 : 5.0,
     Rf2 : Methanol : Chloroform =  0.5 : 9.5.
Similarly, other compounds (VIa-j)  were synthesized. The physical
data are recorded in Table No. 6.
(D)  Antimicrobial activity of 6-Fluoro-7-N-ethyl piperazinyl, / N,N-dichlo-
roethyl /  morpholinyl /  N-phenyl piperazinyl / N-methyl piperazinyl /piperazi-
nyl /  N,N-diethyl  /  2-pyridyl amino  / 2-pyrimidyl amino -1-N-propyl-1,4-
dihydro quinoline-4-one-3-carboxylic acids(VIa-j ).
Antimicrobial activity testing was carried out as described in Part-1,
Section-I, page No.30-31. The MIC values of test solution are recorded in Table
No. 6A,6B,6C.
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Alkane
(methyl &
methylene)
Aromatic and
ring skeletal
vibration
Ketone
(4-quinolone)
(acid)
Halogen
Subtitution
Frequency in cm-1
Observed Reported
Reference
2975 - 2850
2900 - 2800
1470 - 1435
1385 - 1300
3080 - 3010
1600 - 1450
1150 - 1050
  825 -   800
1340 - 1250
1710 - 1640
1740 - 1650
1400 - 1080
Type  Vibration  mode
C-H (asym. str., m s)
C-H (sym. str., m)
C-H (asym. def., m)
C-H (sym. def., m)
C-H (str., v)
C=C & C-C (str., v)
C-H (i.p. def., m)
C-H (o.o.p. def., m)
C-N (str., v)
C=O (str., s)
C=O (str., s)
C-F (str., b)
IR SPECTRAL STUDY OF 6-FLUORO(7-N-ETHYL PIPERIZINYL)-1-N-
PROPYL-1,4-DIHYDROQUINO-LINE-4-ONE-3-CARBOXYLIC ACID (VIa).
2922.5
2870.1
1458.2
1346.3
3036.0
1537.3
1147.6
806.2
1323.2
1695.4
1726.3
1178.5
* Abbreviations : s = strong, m = medium, w = weak, v = variable, b = broad, sh = sharp.
309
309
311
311
312
311
311
312
312
312
309
N
O O
OH
CH 3
F
N
N
CH 3
(VIa)
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NMR  SPECTRAL STUDY OF 6-FLUORO-(7-N-PHENYL PIPERIZINYL)-1-N -
PROPYL-1,4-DIHYDROQUINO-LINE-4-ONE-3-CARBOXYLIC ACID (VId).
Signal
No.
Signal Position
(δ ppm) Multiplicity
Inference
1
2
3
4
5
6
7
8
9
triplet
multiplet
triplet
triplet
singlet
singlet
multiplet
singlet
singlet
- CH3(a)
- CH2(b)
- CH2(c)
- CH2(g,g’)
-CH2(g’’,g’’’)
- Ar-H(d)
- Ar-H(f,f’,f’’)
- Ar-H(e,e’,e’’)
- CH(i)
- O-H(h)
3H
2H
2H
8H
1H
3H
3H
1H
1H
1.0000-1.0368
1.9055-2.0595
4.4669-4.4699
3.2828-3.2898
7.3258
7.9378
8.1881-8.2181
9.0258
14.6975
Relative No.
of Protons
N
F
O O
OH
CH3
N
N
a
b
c
d
e
e'
e''
f
f'
f''
g
g'
g''
g'''
h
i
(VId)
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N
CH3
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CH3
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CH3
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NH
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CH3
F
N
NH
NN
N
CH3
m/z = 361
m/z = 283 (M+2)
m/z = 317
m/z = 266
m/z = 239 (M+2)
m/z = 212 (M+1)
m/z = 169
m/z = 142 (M+2)
NN
NH
N
O
CH3
m/z = 184 (M+2)
N
CH3
F
N+
CH3
N
H
m/z = 132
(VIa)
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           S. pyogens MTCC-442                                                 S. aureus MTCC-96
Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIIa-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
TABLE NO. 6A : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 6-FLOURO-7- N-ETYHL PIPERAZINYL / N,N-DICHLO-
ROETYL /  MORPHOLINYL /  N-PHENYL PIPERAZINYL / N- METHYL PIPERAZINYL / PIPERIZINYL /  N,N- DIETHYL  /
2-AMINO PYRIDINYL / 2-AMINO PYRIMIDINYL-4-OXO-1-N-PROPYL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC AC-
IDS (VIa-j) .(Different Inhibition Concentration in μg/ml).
5 25 50 100 250
- 12 14 15 21
- 12 14 15 18
- 12 13 14 17
- 11 12 15 17
- 12 13 15 20
- 11 12 15 18
- 10 13 16 17
- 11 12 15 17
09 12 13 15 21
- 11 14 15 18
 Compd
 No.
VIa
VIb
VIc
VId
VIe
VIf
VIg
VIh
VIi
VIj
                R
N-Et-C4H9N2
N-(C2H4-Cl)2
N-(C2H4)2-O
N-Ph-C4H9N2
N-Me-C4H9N2
N-(C2H4)2NH
N-(C2H4)2CH2
N-(CH2CH3)2
-2-NH-(C5H4N)
-2-NH-(C4H3N2)
N.B.(-): No Activity  nN.
5 25 50 100 250
- 10 14 16 17
- 12 13 15 17
- 12 14 17 18
- 11 12 14 15
- 13 16 17 18
- 11 14 15 17
10 14 16 18 21
12 15 18 19 23
- 10 13 14 15
10 12 15 17 19
11 14 16 18 19
10 13 19 20 20
16 19 21 21 22
18 19 20 21 21
10 13 14 16 18
12 14 19 20 21
17 19 21 22 22
19 22 25 26 28
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
VIa
VIe
VIi
VIg VIe VIaVIh VIaVIj VIa
VIh VIg VIbVIj VIc VIe
VIj VIh VIe VIe VIg
VIf VIg VIh
VIg VIh
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Antibactrial activity (Zones of inhibition in mm)
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIIa-j) with known choosen standard drugs
 Standard drug       Antibacterial activity
5 25 50 100 250
- 13 14 15 16
09 12 16 18 19
- 14 16 17 18
10 15 17 18 19
- 10 12 14 16
- 08 12 14 15
12 17 18 19 21
- 10 12 15 17
- 08 11 14 15
- 12 15 17 18
 Compd
 No.
VIa
VIb
VIc
VId
VIe
VIf
VIg
VIh
VIi
VIj
                R
N-Et-C4H9N2
N-(C2H4-Cl)2
N-(C2H4)2-O
N-Ph-C4H9N2
N-Me-C4H9N2
N-(C2H4)2NH
N-(C2H4)2CH2
N-(CH2CH3)2
-2-NH-(C5H4N)
-2-NH-(C4H3N2)
N.B.(-): No Activity  nN.
5 25 50 100 250
- 11 12 14 16
- 10 13 15 17
- 13 15 17 21
- 11 13 15 17
- 10 12 14 14
- 11 12 13 15
- 14 16 18 20
- 09 10 13 14
- 10 12 13 15
- 10 12 14 16
                          E. Coli MTCC-443                                                        P. Aeruginosa MTCC-424
14 15 16 19 20
14 17 23 23 23
20 23 28 28 28
22 25 26 27 29
14 15 15 18 20
14 17 18 19 21
20 23 24 26 27
18 19 21 23 23
 Amoxiciline
 Chloramphenicol
 ciprofloxacin
 Norfloxacin
VId VIb VIg VIg
VIg VIc
VId
VIg
VIc VIg VIc
VIg VIg
TABLE NO. 6B : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 6-FLOURO-7- N-ETYHL PIPERAZINYL / N,N-
DICHLO-ROETYL /  MORPHOLINYL /  N-PHENYL PIPERAZINYL / N- METHYL PIPERAZINYL / PIPERIZINYL /  N,N-
DIETHYL  /  2-AMINO PYRIDINYL / 2-AMINO PYRIMIDINYL-4-OXO-1-N-PROPYL-1,4-DIHYDROQUINOLINE-3-CAR-
BOXYLIC ACIDS (VIa-j) .(Different Inhibition Concentration in μg/ml).
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- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
 Comparative activity of (IIIa-j) with known choosen standard drugs
5 25 50 100 250
- 21 22 23 25
- 19 21 22 25
- 21 23 25 27
- 23 23 25 25
- 20 20 22 22
- 19 21 24 25
- 18 20 23 25
- 20 22 23 25
- 19 21 23 23
- 20 22 25 27
 Compd
 No.
VIa
VIb
VIc
VId
VIe
VIf
VIg
VIh
VIi
VIj
                R
N-Et-C4H9N2
N-(C2H4-Cl)2
N-(C2H4)2-O
N-Ph-C4H9N2
N-Me-C4H9N2
N-(C2H4)2NH
N-(C2H4)2CH2
N-(CH2CH3)2
-2-NH-(C5H4N)
-2-NH-(C4H3N2)
N.B.(-): No Activity  nN.
5 25 50 100 250
- 20 22 25 27
- 22 25 25 25
- 18 20 22 25
- 18 19 22 25
- 21 22 23 25
- 19 22 25 25
- 18 18 21 22
- 22 22 24 24
- 18 20 21 22
- 21 21 23 24
                 A. niger MTCC-282                                                  A. Clavatus  MTCC-1323
Antifungal activity (Zones of inhibition in mm)
 Standard drug       Antifungal activity
Griseofulvin
Nystatin
19 23 25 25 28
18 19 24 29 29
18 21 22 22 24
18 21 24 25 26
VIb VIa  VIaVIh VIaVIh
VIe VIb  VIbVIj VIbVIj
VIh VIe  VIc VIc
VIj VIf  VId VId
VIh  VIe VIe
 VIf VIf
VIaVIh VIc
VIbVIi VId
VIcVIj VIj
VId
VIe
VIf
TABLE NO. 6C : COMPARATIVE ANTIMICROBIAL ACTIVITY OF 6-FLOURO-7- N-ETYHL PIPERAZINYL / N,N-DICH-
LOROETYL /  MORPHOLINYL /  N-PHENYL PIPERAZINYL / N- METHYL PIPERAZINYL / PIPERIZINYL /  N,N-DIET-
HYL  /  2-AMINO PYRIDINYL / 2-AMINO PYRIMIDINYL-4-OXO-1-N-PROPYL-1,4-DIHYDROQUINOLINE-3-CARBOXY-
LIC ACIDS (VIa-j) .(Different Inhibition Concentration in μg/ml).
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dinitro phenothiazines.” By Arif B. Siddiqui, G.G.Dubal & V.H. Shah in
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? A facile synthesis of pyrazolo [3,4-d] pyrimidines.” By Trivedi, A. R.; G. G.
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? “A Facile Synthesis of Some Indolylazetidinones and Substituted
Indolylthiazolidinones.” By Pranav R Vachharajani, Bhavin R Trivedi,
Gaurang G Dubal, Manish J Solanki in Organic Chemistry : An Indian
Journal (Accepted   In press)
186
PARTICIPATION IN CONFERENCES / WORKSHOPS / SEMINARS:
? “Two days National workshop on updates in Process & Medicinal  chemistry”
on 3-4 March, 2009 organized by Department of Chemistry ,Saurashtra
University, Rajkot.
? National Workshop on Management and use of chemistry databases and
patent literature during February 27th to 29th – 2008 jointly organized
Department of Chemistry, Department of Computer Science, Computer
Centre-Saurashtra University and Gujarat Council On Science & Technology
(GUJCOST)-Gandhinagar held at Rajkot.
? International Conference On The Interface Of Chemistry-Biology In
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